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11. INTRODUCTION
1. 1. History of Celiac disease
A physician, named Aretaeus of Cappadocia, influenced by Greek culture and living in the first
century AD, wrote about “The Coeliac Affection”. In fact, he named it “koiliakos” after the
Greek word “koelia” (abdomen). His description was: “If the stomach is irretentive of the food
and if it passes through undigested and crude, and nothing ascends into the body, we call such
persons coeliacs”.
In 1888, English doctor Samuel Gee, a leading authority in paediatric diseases, took full credit for
the modern description of celiac disease, when giving a lecture to medical students on the “celiac
affection,” the milestone description of this disorder in modern times. Gee first described celiac
disease (CD) as a disorder with onset usually between 1 and 5 years of age, with diarrhea,
abdominal distension and failure to thrive as the most important symptoms (1).
The disease cause was unknown, but it was noticed that patients recovered when they were put on
a restricted diet. Different diets were used; in 1924 Sidney Hass recommended that bananas were
the answer to the condition. He published a medical paper outlining his "banana diet" which
restricted other forms of carbohydrates, thereby unknowingly cutting out many foods containing
gluten. In 1941, the Dutch paediatrician Willem Karel Dicke discovered that children with CD
benefited when treated with a wheat-free diet. This understanding came about due to the recovery
of children during the war, when grains such as wheat, rye and barley were in short supply.
The next major breakthrough came in the mid-50s, when Margot Shiner described a new jejunal
biopsy apparatus with which she successfully reached and biopsied the distal duodenum. In the
mid to late 60’s, it had become clear that CD could be diagnosed with the jejunal biopsy showing
atrophy of the villi (2).
The anti-gliadin antibodies were detected and reported by Berger in 1964. While, seven years
later Seah et al. identified, for the first time, not an anti-food protein, but an actual auto-antibody
in the serum of celiac children: the anti-reticulins (3).
2In late 80’s, many studies declare that almost all CD patients share a particular combination of a
human leucocyte antigen II (HLA class II) DQA and DQB genes; i.e. they may share a particular
cis- or trans-encoded DQα/ß heterodimer (4, 5).
In Germany, Schuppan et al., were attempting to identify the target antigen of anti-endomysial
antibody (EMA) that was being used so successfully as a diagnostic screening test for CD. They
discovered that the target antigen of anti-endomysial antibody was an enzyme, tissue
transglutaminase, also termed TG2 (6).
In the late 80’s, a large multicentre Italian study demonstrated that by relying on strict clinical
and laboratory criteria, a correct diagnosis of CD could be reached in 95% of cases by limiting to
the one initial biopsy, and new diagnostic guidelines were published in 1990 by the European
Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) (7).
After 90`s, CD was increasingly accepted as an example of an autoimmune disease, associated
with a specific HLA class II- DQA and DQB genes (either DQ2 or DQ8) and the missing
autoantigen was finally identified in the enzyme “tissue transglutaminase”. At long last, there was
universal acceptance that celiac disease is an autoimmune condition whose trigger (gluten) and
autoantigen (tissue transglutaminase) are known.
1.2. Epidemiology of CD
In the last decades a high number of epidemiological data have been reported. Nowadays, celiac
disease is one of the most frequent genetically based disorders in humans, among both children
and adults.
CD originally thought to almost exclusively affect white Europeans, is now known to be widely
distributed worldwide. Epidemiological studies conducted in areas supposedly free of CD,
including Africa, the Middle East, Asia and South America, show that the disease was previously
underdiagnosed. This provides evidence that CD is one of the most common genetic diseases,
resulting from both environmental (gluten) and genetic factors.
For the majority of countries, the CD prevalence is unknown. It must be noted that some studies
report prevalence of CD based on serology, others on celiac compatible small bowel biopsies
(SBB) and a few on serology, biopsy and response to gluten challenge.
3Europe is historically considered a geographical area at high frequency, with a prevalence of 1%
(8), which may be higher in Northern European countries (9-11).
The Scandinavian countries, Ireland, and the United Kingdom’s population tended to show a
higher prevalence of CD of approximately 1.0%-1.5%. A study of SBB obtained from healthy
Dutch blood donors shows that the prevalence of CD-compatible biopsies of 1:330 (12). The
prevalence of CD among 3654 children (age range, 7-16 years) in Finland was at least 1:99 based
on serum autoantibodies and SBB abnormalities (13).
Although it was thought that some countries, including United States, were exempt from this
disease, recently it has been shown that a prevalence is similar as in Europe, namely 0.5%-1.0%
of the general population (14).
Higher frequency of CD have also been shown outside Europe and the United States among
populations of predominantly European extraction (e.g., New Zealand and Australia). Many
studies have shown that CD is not exclusive for industrialized countries, there is an increased
incidence even in North Africa, Middle East and India, with an incidence overlapping those of
European countries (15-17).
Iceberg model is used to describe the epidemiology of CD (18). The typical CD cases, usually
diagnosed because of suggestive complaints, make up the visible part of the celiac iceberg,
expressed by the incidence of the disease in quantitative terms. In developed countries, however,
for each diagnosed case of CD, an average of five cases remain undiagnosed (the submerged part
of the iceberg) (19).
The crude incidence is defined as the number of new cases per 100,000 population-at-risk per
year and cumulative incidence as the number of new cases per 1,000 live births.
The crude incidence of CD in adults varies from lows of 1.27 in Denmark and 3.08 in England to
a high of 17.2 cases per 100,000 patient per years in Finland (20-22) where specific efforts have
been undertaken to encourage screening for CD. The crude incidence of CD in children age 0 to
15 years varied from 2.15 to 51 cases per 100,000 patient-years, while the relative risk (RR) of
CD was greatest for the 0 to 2-years old age group, as well as for females, and varied from 32.26
to 42.4 and from 1.9 to 3.34, respectively (23-25). The cumulative incidence at age 5, when
reported, varied between 0.089 and 9 cases per 1,000 live births (26).
Regarding to gender distribution, females seem to be more frequently affected, although data on
sex differences are poor (27-29). The female to male ratio in the patients age groups 0-15 years
4range from 1.6-3:1. This difference was not found in screening studies, suggesting the
underdiagnosing in daily practice in males (30, 31).
1.3. Definition and classification of CD
CD is an immune-mediated systemic disorder elicited by gluten and related prolamines in
genetically susceptible individuals and characterized by the presence of a variable combination of
gluten-dependent clinical manifestations, CD-specific antibodies, HLA-DQ2 or HLA-DQ8
haplotypes, and enteropathy. CD-specific antibodies comprise autoantibodies against TG2,
endomysial antibodies (EMA), and antibodies against deamidated forms of gliadin peptides
(DGP) (32).
CD is triggered by the ingestion of gluten and related prolamines that are harmful to patients with
CD. The term gluten indicates a complex of water insoluble proteins (gliadins and glutenins)
found in wheat. Other prolamins showing similar immunogenic properties are also found in rye
(secalins), barley (hordeins) and other closely related grains (33).
Gluten is poorly digested in the human intestine with or without CD. Gluten peptides cross intact
into the submucosa of the small intestine, where the human enzyme TG2, also referred to as
tissue transglutaminase (tTG) deamidates gluten peptides, allows for high-affinity binding to
HLA-DQ2 and HLA-DQ8 molecules, subsequently triggering an inflammatory reaction in
patients with CD (34).
Several classifications of CD have been used, most important with distinction forms according to
Oslo classification: classical, non-classical, symptomatic, subclinical and potential CD (35, 36).
Classical CD refers to a presentation with signs and symptoms of malabsorption: diarrhoea,
steatorrhoea, and weight loss or growth failure. Children with Classic CD are often characterized
by failure to thrive, diarrhoea, muscle wasting, poor appetite and abdominal distension. It is
usually manifested between ages six to 24 months (37).
Non-classical seem to be one of the most common forms. These patients generally have little to
no gastrointestinal (GI) symptoms, but seek medical attention because of other reasons, such as:
iron deficiency, osteoporosis, short stature, or infertility. Patients with monosymptomatic disease
(other than diarrhoea or steatorrhoea) usually have non-classical CD.
5Subclinical CD is a term used to describe the disease that is below the threshold of clinical
detection without signs or symptoms sufficient to trigger CD testing in routine practice.
Symptomatic CD is characterized by clinically evident GI and/or extraintestinal symptoms
attributable to gluten intake. The clinical manifestations of CD vary from little to a wide
spectrum of symptoms.
Potential CD is defined by the presence of CD-specific antibodies and compatible HLA, but
without histological abnormalities in duodenal biopsies. The patient may or may not have
symptoms and signs and may or may not develop a gluten dependent enteropathy later.
1.4. Immunopathogenesis of CD
Susceptibility to CD, its activation and perpetuation, involve a combination of environmental and
genetic factors through some immunological mechanisms (38).
The role of dietary proteins - CD is triggered by the ingestion of gluten and related prolamines
that are harmful to patients with CD. The term gluten indicates a complex of water insoluble
proteins (gliadins and glutenins) found in wheat. Other prolamins showing similar immunogenic
properties are also found in rye (secalins), barley (hordeins) and other closely related grains.
Genetic factors - Nowadays, it is known that CD is associated with specific MHC class II alleles
that map to the HLA-DQ locus. Moreover, the presence of specific HLA-DQ alleles is necessary,
although not sufficient, for the phenotypic expression of CD in virtually all affected individuals,
irrespective of geographic location.
The HLA-DQ2 heterodimers, that confer susceptibility to CD, are formed by a β chain encoded
by the allele HLA-DQB1*02 (either HLA-DQB1*02:01 or *02:02) and an α chain encoded by
the allele HLA-DQA1*05. The HLA-DQ2 heterodimer is present in at least 90%–95% of patients
with CD, although a very small number of CD patients in whom only one of these DQ2 alleles is
present have been reported (that is, HLA-DQB1*02 or, rarely, HLA-DQA1*05) (39, 40). While,
HLA-DQ8 heterodimer found in the remaining 5%–10% of patients with CD, is formed by the β
chain and α chain encoded by HLA-DQB1*03:02 and HLA-DQA1*03, respectively (41).
Adaptive immunity - activation of HLA-DQ–restricted mucosal T cells and the role of tissue
TGase - HLA-DQ2 and HLA-DQ8 heterodimers on antigen presenting cells (APCs) can bind
and subsequently present “gluten” peptides to populations of CD4+ T cells in the lamina propria
6of the small intestine (42). TG2-ase also has a high avidity for “gluten” peptides and, under
certain conditions (for example, low pH) and in the absence of lysine residues, can deamidate
glutamine, which converts neutral glutamine to negatively charged glutamic acid while, HLA-
DQ2 and HLA-DQ8 favours the binding of peptides with negatively charged (43, 44). In a
further series of events, the APCs present some of these peptides to HLA-DQ2– and HLA-DQ8–
restricted populations of CD4+ T cells that become activated and release mediators that
ultimately lead to tissue damage.
Role of innate immunity and intraepithelial lymphocytes (IELs) in CD - Recent studies suggest
that activation of the innate immune system is important in the pathogenesis of CD. In particular,
an increase in the number of IELs in the mucosa of the small intestine is a characteristic feature
of CD (45,46). Following activation, IELs from patients with CD change from being typical
antigen specific T cells to being natural killer (NK) - like cells able to mediate epithelial cell
damage through the recognition of stress-induced molecules on intestinal epithelial cells. The
cytokine interleukin 15 ( IL-15) takes centre stage in this process (47).
1.5. Clinical presentation of CD
Recognition and assessment of coeliac disease can be difficult because of the variety of
presenting signs and symptoms that can vary according to patients' age (48). In children, CD can
present with a broad range, from absolute absence of symptoms to pronounced clinical GI or
extraintestinal manifestations (32, 49) (see Table 1).
Table 1. Clinical manifestations of CD
GI manifestations Extraintestinal manifestations
-Chronic diarrhea, -Failure-to-thrive and stunted growth
-Chronic constipation -Delayed puberty and/or amenorrhea
-Abdominal pain -Anaemia and chronic fatigue
-Nausea and vomiting -Decreased bone mineralisation (osteopenia
/osteoporosis) and dental enamel defects
-Distended abdomen -Irritability and neuropathy
-Steatorrhea -Arthritis/ arthralgia
-Increased levels of liver enzymes
7GI manifestations usually appear in clinically diagnosed childhood CD, mostly represented by:
chronic diarrhoea (in about 50% of patients), abdominal pain, chronic constipation, nausea
vomiting, distended abdomen.
A shift from GI symptoms to extraintestinal symptoms seems to have occurred in children with
CD. It is unclear whether this finding reflects a true clinical variation or an improved recognition
of non-gastrointestinal forms of CD because of increased awareness of the disease.
Researchers have found good evidence that failure to thrive and stunted growth may be caused by
CD. The risk of CD in patients with isolated stunted growth or short stature (SS) has been
calculated as 10% to 40%. On the other hand, in some populations, CD is diagnosed in
approximately 15% of children with iron-deficiency anaemia (50).
The following findings may also be present when CD is diagnosed: chronic fatigue, irritability,
neuropathy, epilepsy, arthritis/arthralgia, osteoporosis, alopecia, amenorrhoea and/or delayed
puberty, aphthous stomatitis, dermatitis herpetiformis, and abnormal liver biochemistry. The fact
that CD is common and has protean manifestations means that the diagnosis is easily missed
unless physicians and other health care providers include CD in the differential diagnosis of
common conditions such as iron anaemia and vitamin B12 deficiency, mild chronic diarrhea,
recurrent abdominal discomfort, failure to thrive as well as less common manifestations such as
skin rashes, hair loss, neurological disorders, osteoporosis and osteomalacia, unexplained
hypertransaminasemia or infertility.
In brief, the first and most critical step in making a diagnosis of this commonly overlooked
disorder is to think of celiac disease as a diagnostic possibility (51).
1.6. Associated conditions
Since CD is an inflammatory disorder, induced by a known exogenous factor, a set of conditions
can be associated with celiac disease. The term “associated conditions” refers to states that are
found more frequently in affected patients. These conditions include genetic, autoimmune or
neurological disorders (52).
Nowadays, good evidence is in existence for the increased prevalence of CD in patients with
autoimmune diseases such as diabetes mellitus type 1 (T1DM). The prevalence of CD in T1DM
8has been investigated extensively and is 3% to 12%. The Agency for Healthcare Research and
Quality (AHRQ) report a paper that included 21 studies on T1DM with biopsy proven CD. For
all the included studies, the minimum prevalence of CD in T1DM by serology was 1% and the
maximum was 12%. By biopsy, the minimum and maximum prevalence were 1% and 11%,
respectively (53).
In addition, CD occurs more frequently than expected by chance in children with Turner
syndrome (54) or Down syndrome. A 10 to 20-fold increase in CD prevalence has been reported
in subjects with selective IgA deficiency (55).
Moreover, in patients affected by CD it has been reported an increased prevalence (nearly, 2%-
5%) of thyroid disorders (i.e., hyperthyroidism-Graves’s disease or hypothyroidism-Hashimoto’s
thyroiditis), diagnosed either before rather than after the diagnosis of gluten-enteropathy (56).
These two conditions share genetic risk factors represented by HLA-DQ2 and DQ8. HLA-DQ2
and DQ8 haplotypes have been associated with Hashimoto’s thyroiditis, while HLA-DQ2
association is less clear in Graves’ disease.
A potential link between CD and different neurological disorders has been reported. Although
ataxia is a neurological disorder indicated in some patients with CD, the most frequent neurologic
condition in celiac disease subjects is epilepsy, showing a prevalence between 1.2% and 5% (57).
The involvement of the liver is common among patients affected by CD. The prevalence of CD in
Williams syndrome is higher than in the general population from 6% to 9% (58).
Low bone mass is common in subjects with newly diagnosed CD. The mechanism for this effect
may be due to malabsorption of vitamin D and calcium and decreased intake of calcium due to
lactose intolerance. However, low bone mass may be due not only to osteoporosis but also to
osteomalacia. CD among patients with low bone mass have been performed in Europe. CD was
found in 3.4 percent of adults with low bone mass but reduced bone density is common in both
adults and children with CD.
Malignant diseases are more frequent in patients with long-term untreated classical CD. Small-
bowel adenocarcinoma, esophageal and oropharyngeal squamous-cell carcinoma, and non-
Hodgkin’s lymphoma occur more often in CD patients than in healthy control individuals.
CD may be associated with delayed menarche, premature menopause, amenorrhea, recurrent
abortions, and fewer children (59).
9On the other hand, some individuals with CD report diminished quality of life (QOL). One group
of researchers found that age at diagnosis affected perceived QOL, with those diagnosed at a
younger age reporting higher QOL scores (60, 61).
1.7. Family history of CD
Many early case reports documented the occurrence of CD in siblings, identical twins, parent and
child pairs, as well as more extended kindred’s. At least 20 percent of index cases will have an
affected family member if screening is done. Identical twins have a 75–100 percent concordance
rate for the disease. Siblings are at the next highest risk at 7–20 percent concordance rate. It has
been suggested that if siblings share the same HLA disease risk haplotype, their risk approaches
40 percent. These results contribute for future recommendations for CD screening frequency and
follow-up duration of relatives of celiac patients (51, 62).
1.8. Diagnostic tools
1.8.1. Serum antibodies
In many studies, a number of serological markers have been repeatedly shown to be highly
sensitive and specific for untreated CD.
On the basis of the target antigens, serologic tests for celiac disease can be divided into two
groups (18).
1. Autoantibodies:
- Antiendomysial (EMA) and anti-tissue transglutaminase (tTG) antibody tests
IgA EMA bind to endomysium, the connective tissue around smooth muscle, producing a
characteristic staining pattern that is visualized by indirect immunofluorescence. The test result is
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reported simply as positive or negative, since even low titre of serum IgA endomysial antibodies
are specific for CD. The antigen against which antiendomysial antibodies are directed is tTG.
Anti-tTG antibodies. Enzyme-linked immunosorbent assay (ELISA) tests for IgA anti-tTG
antibodies are now widely available and are easier to perform, less observer-dependent, and less
costly than the immunofluorescence assay used to detect IgA endomysial antibodies.
2. Antibodies targeting the offending agent (gliadin):
- Conventional antigliadin antibodies (AGAs) (nowadays considered obsolete for diagnostic
purposes)
- Antibodies against synthetic deamidated gliadin peptides (DGPs) - are recommended in patients
<2 years old, since this may appear earlier than anti-tTG antibodies in very young children with
CD.
Usually all of these antibodies are based on immunoglobulin A (IgA) class. In patients with IgA
deficiency, the same type of antibodies, but of the IgG class, can be detected. Specifically, IgG-
based tests are useful for detecting CD in selected IgA-deficient patients (63, 64).
The sensitivity and specificity of anti-tTG on diagnosis of CD is well documented. Assays using
human recombinant tTG, improved high sensitivity of about 98 (78-99) percent and similar
specificity of 98 (91-99) percent (65).
According to systematic reviews and studies in low-risk and high-risk populations, EMA-IgA is
both highly sensitive and specific. Most studies demonstrate EMA sensitivities in excess of 95%
(86%-100%) in children and 90% in adults with specificities above 98% (97%-100%) in both age
groups (66).
Depending on different population studies, IgA anti-DGP can be nearly as sensitive as IgA anti-
tTG (67).
Nevertheless, recent studies have shown that IgA anti-tTG perform significantly better and is
significantly less costly than IgA anti-DGP testing. A review done in 2510 published articles,
conclude that IgA-EMA and IgA-anti-TG2 tests appear highly accurate to diagnose CD (68).
AGA tests are no longer routinely recommended for diagnosing CD, because of their lower
sensitivity and specificity.
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1.8.2. Small bowel biopsies
CD affects the mucosa of the proximal small intestine, with damage gradually decreasing in
severity towards the distal small intestine, although in severe cases the lesions can extend to more
distal areas and patchy distribution, in some cases.
The definitive diagnosis of celiac disease is made by identification of characteristic histologic
changes on biopsy of the duodenum during upper gastrointestinal endoscopy while the patient
maintains a gluten-containing diet (69).
It has been suggested that villous lesions rarely coexist with histologically normal mucosa
but others describe CD as exhibiting a patchy distribution thus implying a need for multiple
biopsy specimens to secure a diagnosis. Based on this new guidelines on CD, four to six
duodenal biopsies are recommended for evaluation of CD, due to the patchy nature of
histopathology features.
Biopsies should be taken from the bulb (at least 1) and from the second or third portion of the
duodenum (at least 4) (70).
Whole spectrum of histological signs may be present in CD, ranging from a normal villous
architecture to severe villous atrophy. According to the Marsh classification and its modification,
lesions include infiltrative, hyperplastic, and atrophic patterns (71, 72). Consequently, if
histology shows lesions that are consistent with CD (Marsh 2–3), then the diagnosis of CD is
confirmed.
The pathology report should include a description of the orientation, evaluation of villi (normal
or degree of atrophy), crypts, villus/crypt ratio, and number of IELs (73). IELs in numbers
>25/100 epithelial cells suggest an infiltrative lesion. Anyway, histological damage is considered
characteristic, but not pathognomonic, of celiac disease, as similar lesions are seen in several
other disorders.
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1.8.3. Genetic tests in CD
HLA is the name for the Mayor Histocompatibility Complex (MHC) in humans; it is a genomic
region located in the chromosomal position 6p21 and contains a large number of genes related to
the immune response. HLA genes encode antigen presenting proteins that are expressed in most
human cells and are essential for the ability of the organism to distinguish between self and
foreign molecules. As previously mentioned, the HLA region is the most important susceptibility
locus in CD and explains around 40% of the genetic component of the disease.
Molecular studies have revealed that the factors directly implicated are the HLA class II genes
encoding both HLA-DQ2 and -DQ8 molecules (see Figure 1).
More than 95% of patients with CD share the HLA-DQ2 heterodimer, either in the cis (encoded
by HLA-DR3-DQA1*05:01-DQB1*02:01) or the trans configuration (encoded by HLA-DR11-
DQA1*05:05 DQB*03:01/DR7- DQA1*02:01 DQB1*02:02) and most of the remainder have the
HLA-DQ8 heterodimer (encoded by DQA1*03:01-DQB1*03:02) (75, 76).
CD is a multigenetic disorder, which means that the expression of these HLA-DQ2 or HLA-DQ8
molecules is necessary, but not sufficient to cause disease, because approximately 30% to 40% of
the white population holds the HLA-DQ2 haplotype and only 1% develops CD (77). The strong
relation between HLA genetic factors and CD is illustrated by the effect of the HLA-DQ2 gene
dose on disease development; HLA-DQ2 homozygous individuals have at least 5 times higher
risk of disease development compared with HLA-DQ2 heterozygous individuals.
The sensitivity of HLA-DQ2 is high (median 91%; p25–p75 86.3%– 94.0%), and if combined
with HLA-DQ8 (defined that at least one of them is positive), it is even higher (median 96.2%;
p25–p75 94.6%–99.8%), making the chance to have CD for an individual who is negative for
DQ2 and DQ8 very small (78). The specificity of HLA-DQ2 is low (median 74%; p25–p75
65%–80%).
The specificity of HLA-DQ8, evaluated in 9 studies, had a median of 80% (p25–p75 75%–
87.5%). The specificity of the combination HLA-DQ2/DQ8 varies widely in different study
populations, from 12% to 68% with a median of 54%.
As the chance of an individual negative for HLA-DQ2 or HLA-DQ8 having CD is small, the
main role of HLA-DQ typing in the diagnosis of CD is its negative predictive value (96%-98%)
to exclude the disease or to make it unlikely (79-81).
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Figure 1. Association of the HLA locus with CD. HLA-DQ2 molecule is the major factor
conferring risk to CD. Most celiac patients express the heterodimer HLA-DQ2.5, encoded by the
alleles HLA-DQA1*05 ( chain) and HLA-DQB1*02 ( chain), that can be present in cis in the
DR3-DQ2 haplotype or in trans, in the heterozygotes DR5-DQ7 and DR7-DQ2.2. The HLA-
DQ2.2 heterodimer, a variant of HLA-DQ2 encoded by the alleles HLA-DQA1*02:01 and HLA-
DQB1*02:02, confer a low risk to develop the disease. Most of the patients that are negative for
DQ2 express HLA-DQ8, encoded by the DR4-DQ8 haplotype (74).
Literature data reports that the relative risk for celiac disease associated with genotypes (DQ2
and/or DQ8 molecules) could be different among different geographic areas.
The frequency of DQ2 and/or DQ8 heterodimer DQA1*05-DQB1*02, DQ2.5,
in cis or trans configuration, and/or DQA1*03-DQB1*03:02 in the Moroccan population was
found in 87% of patients with CD (82). Slightly higher frequency was reported by Megiorni et al.
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(77), 91% of CD patients carried DQ2 and/or DQ8 heterodimers while among the DQ2/DQ8-
negative individuals, the frequencies of cases carrying DQB1*02 (β2), DQA1*05, or neither of
the two alleles were 6%, 2.1%, and 0.9%, respectively.
In a study from Slovenia in 2006, the DQ2 and DQ8 frequency was reported to be 97.6% (83),
while in 2016 it was reported that frequency of DQ2 heterodimer (in cis and/or trans) in CD
patients was 89.7%, while 5.88% carried DQ8 heterodimer, all together giving a DQ2 and/or
DQ8 frequency in this population of 95.6 % (84).
A study from Libya performed in CD patients found out a DQ2 and/or DQ8 heterodimer
prevalence of 97%, out of them 13% were DQ8 positive (85).
In a study from Serbia, 94.5% (86) of patients carried alleles that encode DQ2 protein variant and
2.7% carried alleles that encode DQ8 protein variant, comprising total of 97.2%. The results of
Rostami-Nejad et al. (87) on Iranian people, 97% of the patients diagnosed with CD had HLA-
DQ2 and/or DQ8 heterodimer, with 83.03% of cases carriers of an HLA-DQ2 heterodimer, either
in homozygous or heterozygous state, while 13.5% were DQ8 carriers.
Anyway, there are some published studies in the literature reporting the highest incidences. In the
study conducted by Sumnik et al. (88) in Czechoslovakia in 2000, the incidence of HLA-
DQ2/DQ8 was 100% as well as in the study conducted by Neuhausen et al. (89) in Israel.
It is recommended that clinicians should not classify patients only as DQ2 and DQ8 positive or
negative, but must also consider the presence of DQB1*02 and DQA1*05 alleles alone,
regardless of their relative low risk for CD development. In study from Brazil, from a total of 100
CD children, 51 (51%) tested positive for DQ2.5 only; 22 (22%) for DQ2.5/DQ2.2; 5 (5%) for
DQ2.2 only; 7 (7%) for DQ2.5/DQ8; 6 (6%) for DQ2.2/DQ8; 6 (6%) for DQ8 only; 1 (1%) was
DQB1*02 positive; 1 (1%) showed low risk predisposing single allele and 1 (1%) tested negative
for all of the searched alleles (90).
Additionally, the recent study (91) reports that 5.8% of patients lacking HLA-DQ2 and HLA-
DQ8 variants, carried DQB1*02 allele, therefore this allele should be recognized as risk allele for
disease occurrence. It may be useful to consider HLA-DQ genotype gradient risk in selecting
individuals who must undergo recurrent clinical and serologic follow-ups, especially in high-risk
groups.
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1.9 New guidelines for CD diagnosis
According to modified European guidelines (32), in symptomatic children with anti-TG2 titres
more than ten times the upper limit of normal (>10 times ULN), SBB for diagnosis of CD may be
omitted. In these circumstances, it is necessary to perform further laboratory tests (EMA, HLA)
to make the diagnosis of CD without biopsies. Moreover, antibody positivity should be verified
by EMA from a blood sample drawn at an occasion separate from the initial test to avoid false-
positive serology. If EMA testing confirms specific CD antibody positivity in this second blood
sample, then the diagnosis of CD can be made and the child can be started on a gluten free diet
(GFD). It is advisable to check for HLA types in patients who are diagnosed without having an
intestinal biopsy to reinforce the diagnosis of CD (see Figure 2 and 3).
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Figure 2. Symptomatic patient. CD = coeliac disease; EMA = endomysial antibodies; F/u = follow-
up; GFD = gluten-free diet; GI = gastroenterologist; HLA = human leukocyte antigen;
IgA = immunoglobulin A; IgG = immunoglobulin G; OEGD = oesophagogastroduodenoscopy;
TG2 = transglutaminase type 2.
Source: European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines
for the Diagnosis of Coeliac Disease Journal of Pediatric Gastroenterology and Nutrition
54(1):136-160, January 2012.
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Figure 3. Asymptomatic patient. See Fig. 2 for definitions.
Source: European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines
for the Diagnosis of Coeliac Disease Journal of Pediatric Gastroenterology and Nutrition
54(1):136-160, January 2012.
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1.10. Treatment and prognosis of CD
The overall accepted treatment for CD is a strict gluten-free diet for life. A balanced GFD based
on a combination of naturally gluten-free foods and certified processed gluten-free products, will
result in symptomatic, serologic, and histological remission in most patients (92, 93). Growth and
development in child return to normal with adherence to the gluten-free diet, and many disease
complications in adults are avoided.
Approximately 70% of patients report an improvement in symptoms within 2 weeks after starting
the gluten-free diet, on the other hand the complete histological resolution is not always achieved,
or may take years (94, 95). Patients who are extremely ill may require hospital admission,
repletion of fluids and electrolytes, intravenous nutrition and, occasionally, steroids. Patients with
severe cases who require hospitalization are described as having a celiac crisis. Patients with
newly diagnosed CD should be referred to an expert dietitian, because the GDF requires
knowledge not only of hidden sources of gluten, but also of healthy gluten-free substitute grains
that provide adequate fibre and nutrients. Upon diagnosis, patients should be tested for
micronutrient deficiencies, including iron, folic acid, vitamin B12, and vitamin D. Patients should
be encouraged to eat natural high-iron and high folate foods, especially if a deficiency in these
minerals is documented. However, not all dietitians are familiar with the intricacies of a GDF,
and for this reason local or national support groups provide most of the required information.
Even thought, the adherence to a GFD is considered a safe treatment for CD, some recent study
reported a relationship between increased heavy metals concentrations especially arsenic, lead,
mercury, and cadmium in CD patients who follow a GFD. This is suspected to be the result of
drinking water and eating food, such as fish and rice-based products (96). Moreover, some other
studies show that the urinary concentration of arsenic was associated significantly with
consumption of rice, which is used as a major gluten-free staple (97). Heavy metals can
bioaccumulate over time and cause an array of adverse health effects. Bioaccumulation of heavy
metals could mainly depend on the food types ingested or their accumulation could also be due to
a genetic predisposition of CD subjects to retain them. Further studies are needed to clarify the
clinical significance of increased heavy metal levels in patients with CD who follow a GFD.
Following a GFD in low and/or middle-income countries (LMIC) has additional barriers. Many
studies from these countries show that the non-availability of gluten-free products is the most
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common barrier to adherence to a strict GFD. This is in part owing to a lack of gluten labelling
on food products in a majority of LMIC. In addition, because of a lack of speciﬁc regulations, the
risk of contamination by gluten is even higher in LMIC and can occur at any stage during its
production and ﬁnal purchase. In LMIC, families with limited resources face an additional risk of
gluten contamination at home, especially if the same utensils are used for storing, cooking and
handling (rolling pin, surface griddle, and oil for frying) gluten containing foods and gluten- free
foods. Furthermore, in the majority of health-care centres in LMIC, there is a lack of dietitians
trained in the nuances of a GFD (98, 99).
Even though the only treatment for CD is a GDF, there is interest among patients in a medical
therapy to replace or help with a GFD. Recent progress made in understanding the pathogenesis
of CD has opened the door for a variety of new non-dietary treatments which may be used at least
as adjunctive therapy (100). However, to the date, only a limited number of experimental
therapies for CD have been assessed in phase I-II randomised, controlled clinical trials.
Larazotide acetate (AT-1001), which is assumed to hinder the paracellular passage of gluten
through the epithelial barrier into the lamina propria by inhibiting tight junctions, has been
studied in almost 100 patients to date, but an effect on hard end points, such as protection of
mucosal integrity, needs to be demonstrated (101). Though fewer patients were studied, evidence
for the efficacy of the endopeptidases contained in ALV003 which break down gluten to less or
non-immunogenic peptide fragments is more obvious. On the other hand, other therapies like
TG2 inhibition, preventing immunogenic potentiation of gluten, therapy targeted at immune cells
(102, 103) blocking the binding of deamidated gluten peptides to CD-specific HLA proteins (104)
or vaccination to induce tolerance to ingested gluten are less advanced but have potential for high
efficacy.
Anyway, CD prognosis is excellent if the treatment begins on time and if it is consistently
implemented. Most of the complications may be prevented by early detection of disease and
lifelong adherence to the GFD. The patient should be regularly monitored and advised for
antibodies check-up (anti tTG) in 6 months after the start of GFD and continue once per year or
less frequently in asymptomatic patients to monitor adherence to GFD.
Challenges for the next decade include reducing the burden of treatment by providing easier
access to inexpensive gluten-free foods and developing non-dietary approaches to increase the
efficacy of treatment.
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2. HYPOTHESIS
HLA DQ2 and DQ8 heterodimers are predisposing genetic factors in Albanian paediatric celiac
disease patients from Kosovo as in the majority of populations studied so far, but specific HLA
haplotypes are expected, especially in DQ2 and/or DQ8 heterodimer negative patients.
3. AIM
3.1. General aim
General aim of the research is to analyze the frequency of HLA-DQ2 and DQ8 heterodimers as
immunogenetic predisposing factors in the population of Albanian celiac disease children from
Kosovo
3.2. Specific aims
 Analyse HLA-DRB1, DQA1 and DQB1 class II polymorphisms in healthy control group
 Analyse HLA-DRB1, DQA1 and DQB1 class II polymorphisms in patient group
 Determine HLA class II predisposing factors by comparison of two studied groups
 Compare the HLA class II gene and haplotype frequency data with other European
populations.
 Determine population specific HLA class II genes and haplotypes involved in disease
predisposition.
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4. MATERIALS AND METHODOLOGY
4.1. Materials
Subjects
The study subject were children aged 17 months to 18 years treated for CD from 2005 to 2016 at
Pediatric Clinic, University Clinical Center of Kosovo (UCCK), as a referral center for CD.
Patients of non-Albanian nationality, and those older than 18 years at the time of diagnosis were
excluded from the study.
Seventy-two paediatric patients were enrolled in the study. All of them were clinically suspected
and had positive serology (anti-TG2) for CD. Among them, 3 were siblings of index cases, thus
they were excluded from further analysis, leading to the patient group consisting of 69 unrelated
children. HLA-A, B, DRB1, DQA1, DQB1 typing has been performed for all patients, while
EMA testing and SBB were performed for 59 and 24 patients, respectively (see Figure 4).
For the clinical data and HLA allele frequency data analysis the entire group of 69 unrelated
patients were divided into 2 groups. In the first group, consisting of 60 patients, CD diagnosis
was established according to old 90’s ESPGHAN guidelines for 24 patients and for 36 patients,
according to 2012 criteria. Nine patients were analysed and discussed separately due to
uncompleted diagnostic tools to fulfil criteria for CD diagnosis.
Separate analysis has also been carried out for three CD siblings, as well as for three healthy
siblings of index cases.
Control group consisted of 124 unrelated healthy children, without a history of autoimmune
diseases, gender and age matched. Out of them, 64 were females and 60 males, while mean age at
the time of sample collection was 8.7 years (SD±5.8), and age ranged from 1 to 18 years.
This cross-sectional retrospective study was performed in Pediatric Clinic, University Clinical
Center of Kosovo (UCCK), as a referral center for CD. HLA typing was performed in Tissue
Typing Center, Department of Transfusion Medicine and Transplantation Biology, Clinical
Hospital Center, Zagreb.
The study was approved by the Ethics Committee of the UCCK and CHC Zagreb.
Informed written consent was obtained from parent/guardian of all children involved in the study.
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Figure 4. Algorithm for CD diagnosis conducted in all seventy-two children. Anti TG2- tissue
transglutaminase 2, EMA-endomysial antibody, SBB-small bowel biopsies, HLA HD- HLA
heterodimer; not done-not tested.
4.2. Methodology
General data (name, gender, age breastfeeding, age at gluten/solid foods introduction in the diet)
and clinical presentation at time of diagnosis were collected through individual interviews. In the
case of young children, the information was provided by parents, whereas adolescents described
their symptoms directly to the physician. Patients` growth parameters were reported following
the current guidelines that recommend the assessment of body weight percentiles in children
according to their age and sex. We used World Health Organization standards to determine the
weight for length (W/L) percentile. All information was reviewed by the investigators to validate
the data and create a clear database. The following parameters were studied: age at diagnosis, the
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delay in diagnosis (which is defined as the interval between the first presentation of symptoms
and the definitive diagnosis of CD), sex, clinical symptoms, family history, associated diseases,
and nutritional status. All cases were divided into 3 age groups: 1–5, 6–10, 11–18 years old.
Clinical presentation, manifested with: diarrhea, abdominal distention, weight loss, failure to
thrive and/or anorexia, was classified as classical CD, while the presence of atypical symptoms
such as abdominal pain, constipation, short stature, vomiting, anaemia, delayed puberty, was
considered to be non-classical.
Serological tests were performed in accredited laboratory; Enzyme-linked immunosorbent assay
by LIAISON® Analyzer (CLIA immunoassay auto-analyzer) was used for anti-TG2 testing. The
manufacturer`s cut-off for positive anti-TG2-IgA antibodies was 15 U/mL, while for anti-TG2-
IgG, 12 U/mL. EMAs were determined by indirect immunofluorescence using monkey
esophagus tissue (Binding Site, Birmingham, UK); with a 1:5 dilution as a cut-off.
Upper gastrointestinal endoscopy with biopsies (UGIE) - was done in department of abdominal
surgery and Institute of Pathology in UCCK. UGIE was done under sedation with a standard
forward-viewing video-endoscope (GIF-Q145, Olympus Optical Co. Ltd., Tokyo, Japan).
Biopsies were taken from both, proximal and distal part of duodenum, including one from the
bulb, following the ESPGHAN recommendation of 4 to 6 specimens per procedure.
Histological examination - the histopathology report has included the description of the
orientation, the presence or not of normal villi, the degree of atrophy and crypt elongation, the
villus/crypt ratio, the number of intraepithelial lymphocytes (IELs). The numbers of IELs were
determined with immunohistochemical staining for CD3 and CD8. The grading was done
according to the revised Marsh-Oberhuber classification, as Marsh I to III (Marsh IIIa, Marsh IIIb,
and Marsh IIIc). Marsh score of 2-3 was considered confirmative for CD.
HLA typing - three milliliters of blood was taken from each child included in the study. EDTA
blood samples were stored frozen at -30oC until all samples were collected. Deoxyribonucleic
Acid (DNA) isolation and HLA typing was performed at Tissue Typing Center, Clinical
Department of Transfusion medicine and Transplantation Biology, KBC Zagreb. Genomic DNA
was purified from whole blood with the MagNA Pure Compact Instrument using the
corresponding commercial kit MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche
Diagnostics GmbH, Penzberg, Germany). Final DNA concentration was 10-200 ng/µl. HLA
genotyping was performed using the Lifecodes HLA-SSO typing procedure based on the
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hybridization of labeled single stranded PCR product to SSO probes. Amplification of DNA was
done using Biometra T professional standard thermocycler (Biometra GmbH, Gӧttingen,
Germany). After the hybridization, the samples were processed using the Luminex200 instrument
(Luminex Corporation, Austin, USA). The Luminex results were analyzed using Quicktype for
Lifecodes 3.3. Software.
DQ heterodimer types were defined by the presence of one of the HLA-DQA1 and DQB1 alleles
in the individual genotype. The first number in HD type stands for the serological equivalent of
DQB1 allele, while the second number stands for DQA1 gene.
Following these rules HD types were denoted as follows:
DQ2.2 = DQA1*02:01-DQB1*02:02;
DQ2.3 = DQA1*03:03-DQB1*02:02;
DQ2.5 = DQA1*05:01/*05:05-DQB1*02:01/*02:02;
DQ4.3 = DQA1*03:03-DQB1*04:02;
DQ4.4 = DQA1*04:01-DQB1*04:02;
DQ5.1 = DQA1*01:01/*01:02/01:03/*01:04-DQB1*05:01/*05:02/*05:03;
DQ6.1 = DQA1*01:02/*01:03- DQB1*06:01/*06:02/*06:03/*06:04/*06:09;
DQ7.3 = DQA1*03:01/*03:02/*03:03-DQB1*03:01;
DQ7.5 = DQA1*05:05-DQB1*03:01/*03:04;
DQ8.3 = DQA1*03:01/*03:02-DQB1*03:02;
DQ9.2 = DQA1*02:01-DQB1*03:03;
DQ9.3 = DQA1*03:03-DQB1*03:03;
The presence of HLA-DQ2.5/DQ8/DQ2.2 genotypes was categorized according to the presence
of CD predisposing HLA heterodimer types, as follows:
DQ2.5/DQX - HD DQ2.5 in single dose, the other heterodimer is other than DQ2.5, DQ8 and
DQ2.2 (e.g. DQA1*01:01, *05:01; DQB1*02:01, *05:02)
DQ2.5cis - DQA1 and DQB1 alleles on the same chromosome
DQ2.5trans - DQA1 and DQB1 alleles on different chromosomes, one on each
DQ8/DQX - HD DQ8 in single dose, the other heterodimer is other than DQ2.5, DQ8 and DQ2.2
(e.g. DQA1*01:01, *03:01; DQB1*03:02, *05:02)
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DQ2.2/DQX - HD DQ2.2 in single dose, the other heterodimer is other than DQ2.5, DQ8 and
DQ2.2 (e.g. DQA1*01:01, *02:01; DQB1*02:02, *05:02)
DQ2.5/DQ2.5 - HD DQ2.5 in double dose, homozygous genotype (e.g. DQA1*05:01, *05:01;
DQB1*02:01, *02:01)
DQ8/DQ8 - HD DQ8 in double dose, homozygous genotype (e.g. DQA1*03:01, *03:01;
DQB1*03:02, *03:02)
DQ2.2/DQ2.2 - HD DQ2.2 in double dose, homozygous genotype (e.g. DQA1*02:01, *02:01;
DQB1*02:02, *02:02)
DQ2.5/DQ8 - HD DQ2.5 and DQ8 in single dose each, heterozygous genotype (e.g.
DQA1*03:01, *05:01; DQB1*02:01, *03:02)
DQ2.5/DQ2.2 - HD DQ2.5 and DQ2.2 in single dose each, heterozygous genotype (e.g.
DQA1*02:01, *05:01; DQB1*02:01, *02:02)
DQ8/DQ2.2 - HD DQ8 and DQ2.2 in single dose each, heterozygous genotype (e.g.
DQA1*02:01, *03:01; DQB1*02:02, *03:02)
DQX/DQX - both heterodimers other than DQ2.5, DQ8 and DQ2.2 (e.g. DQA1*01:01, *01:02;
DQB1*05:02, *06:03)
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4.3. Statistical analyses
Descriptive statistics were presented as means and standard deviations (SD).
HLA-A, B, DRB1, DQA1 and DQB1 allele frequencies were calculated by the GeneRate
program (http://geneva.unige.ch/ahpd/). The Hardy-Weinberg equilibrium, estimates of haplotype
frequencies and measures and tests of significance for linkage disequilibrium (LD) were
performed using the software PyPop (Python for Population Genomics), a software for large-
scale HLA population analyses, originally developed for the analysis of data for the 13th
International Histocompatibility Workshop and Conference (105).
The significance of differences in allele and haplotype frequencies among patients and controls
were evaluated using the chi square test, while Fisher’s exact test was used if any of the values in
2x2 tables less than 5. Sensitivity, specificity, positive predictive value, and negative predictive
value have been calculated using standard 2x2 contingency table. The strength of association
between allele/haplotype polymorphisms and disease risk was assessed by odds ratio (OR) with
the corresponding 95% CI. A p value of <0.05 was considered statistically significant. Analyses
were performed using MedCalc Version 18.10.2. and SPSS software (SPSS Statistics for
Windows, Version 22.0. IBM Corp., Armonk, NY, USA).
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5. RESULTS
5.1. Healthy control group
Control group consisted of 124 unrelated healthy children, without a history of autoimmune
diseases, gender and age matched. Out of them 64 were females and 60 males while mean age at
the time of sample collection was 8.7 years (SD±5.8), and age ranged from 1 to 18 years. All
individuals have been typed for HLA-A, B, DRB1, DQA1 and DQB1 gene and allele
polymorphisms.
5.1.1. HLA-A, -B and DRB1 gene frequencies
The estimated gene frequencies for the HLA-A, B and DRB1 loci studied in 124 healthy children,
are shown in Table 2. Sixteen HLA-A, 24 HLA-B and 13 HLA-DRB1 different genes were
detected in the control group. At HLA-A locus, the most frequent gene, A*02 was present with a
frequency of 33%. Three other genes exhibited frequencies over 10% (A*24, A*03, and A*01),
and together with A*02 represent 66% of all HLA-A genes detected. Three genes were not
detected, HLA-A*34, A*36 and A*80.
At HLA-B locus, out of twenty-four identified, ten alleles were present at >3% contributed
77.44% of total. The most frequent one was B*51 with a frequency of 16% and together with
B*18, and B*35 which had a frequency greater than 10%, represent 42% of all B genes detected.
Twelve HLA-B genes were not detected, B*42, *45, *46, *48, *54, *59, *67, *73, *78, *81, *82
and *83. Out of thirteen HLA-DRB1 genes detected, four genes had a frequency higher than 10%:
the most frequent one HLA-DRB1*11 (22.18%) followed by HLA-DRB1*13 (14.52%), HLA-
DRB1*16 (13.71%) and HLA-DRB1*04 (11.26), representing jointly 61.67% of the total.
The less frequent genes at all three loci, present in only one individual, were A*31, A*66, B*50
and DRB1*09.
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Table 2. HLA-A, -B and DRB1 gene frequencies in the control group
CONTROL GROUP (N=124)
A* n GF (%) IF (%) B* n GF (%) IF (%) DRB1* n GF (%) IF (%)
01 26 10.48 21 07 15 6.05 12 01 10 4.03 8
02 81 32.66 65 08 14 5.65 11 03 18 7.26 15
03 27 10.89 21 13 6 2.42 5 04 28 11.26 23
11 10 4.03 8 14 3 1.21 3 07 17 6.85 13
23 9 3.63 7 15 9 3.63 7 08 5 2.02 4
24 30 12.10 24 18 33 13.31 26 09 1 0.40 1
25 2 0.81 2 27 6 2.42 5 10 4 1.61 3
26 16 6.45 13 35 31 12.50 25 11 55 22.18 44
29 3 1.21 2 37 5 2.02 4 12 4 1.61 3
30 5 2.02 4 38 15 6.05 12 13 36 14.52 29
31 1 0.40 1 39 6 2.42 5 14 18 7.26 15
32 16 6.45 13 40 13 5.24 10 15 18 7.26 15
33 2 0.81 2 41 4 1.61 3 16 34 13.71 27
66 1 0.40 1 44 14 5.65 11
68 17 6.85 13 47 3 1.21 3
69 2 0.81 2 49 8 3.23 6
50 1 0.40 1
51 40 16.13 32
52 3 1.21 3
53 4 1.61 3
55 3 1.21 3
56 2 0.81 3
57 7 2.82 6
58 3 1.21 3
N - number of tested individuals; n - number of genes detected;
GF % - gene frequency, in percentage;
IF % - individuals positive for the gene, in percentage
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5.1.2. HLA-DQA1, -DQB1 allele frequencies
The HLA-DQA1 and HLA-DQB1 allele frequencies of 124 examined healthy children are listed
in Table 3.
Within DQA1 alleles, out of eleven detected, two alleles had a frequency higher than 20%: the
most frequent one DQA1*01:02 (26.6%) and DQA1*05:05 (25.00%); together with the *01:01
present at 12.5%, representing jointly 64.1% of the total.
Fifteen DQB1 alleles were identified. Within DQB1 alleles, two alleles had a frequency higher
than 10%: the most frequent one DQB1*03:01 (26.61%) and DQB1*05:02 (14.52%),
representing jointly 41.13% of the total. The less frequent ones were DQA1*01:04, DQB1*03:04
and DQB1*06:01 which were present in only one individual.
Table 3. HLA-DQA1, -DQB1 allele frequencies in the control group
N - number of tested individuals; n - number of observed alleles;
AF % - allele frequency, in percentage;
IF % - individuals positive for the allele, in percentage
CONTROL GROUP (N=124)
DQA1* n AF (%) IF (%) DQB1* n AF (%) IF (%)
01:01 31 12.50 25 02:01 18 7.26 15
01:02 66 26.61 53 02:02 19 7.66 15
01:03 18 7.26 15 03:01 66 26.61 53
01:04 1 0.40 1 03:02 20 8.06 16
02:01 17 6.85 14 03:03 2 0.81 2
03:01 22 8.87 18 03:04 1 0.40 1
03:02 3 1.21 2 04:02 6 2.42 5
03:03 4 1.61 3 05:01 14 5.65 11
04:01 5 2.02 4 05:02 36 14.52 29
05:01 19 7.66 15 05:03 18 7.26 14
05:05 62 25.00 50 06:01 1 0.40 1
06:02 13 5.24 10
06:03 18 7.26 15
06:04 10 4.03 8
06:09 6 2.42 5
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5.1.3. Two-, three- and five-locus haplotype frequencies
HLA-A,-B two-locus haplotype analysis revealed HLA-A*02-B*51 as the most frequent one
found at 10.68% frequency, followed by HLA-A*02-B*18 and HLA-A*24-B*35, with a
frequency of 5.43% and 4.93%, respectively. A total of 90 different haplotypes were detected,
with 43 haplotypes present only once, while 8 different haplotypes occurred 5 or more times,
representing 35% of a total number of haplotypes in controls.
HLA-A,-B,.DRB1 three-locus haplotype analysis revealed 141 different haplotypes, among
which 95 haplotypes occured only once. Five haplotypes were present 5 or more times and
together represented 18% of all haplotypes. The most frequent one was HLA-A*02-B*08-
DRB1*11 (6.05%).
HLA-DRB1-DQA1-DQB1 three-locus haplotype analysis showed that HLA-DRB1*11-
DQA1*05:05-DQB1*03:01 and HLA-DRB1*16-DQA1*01:02a-DQB1*05:02 were the most
frequent haplotypes, with a frequency of 21% and 13%, respectively. A total of 32 different
haplotypes were detected, with 14 haplotypes present only once.
Two most frequent five-locus haplotypes was found to be HLA-A*02-B*11-DRB1*18-
DQA1*05:05-DQB1*03:01 and HLA-A*02-B*51-DRB1*14-DQA1*01:01-DQB1*05:03 with
frequency of 6.45 % and 3.62%, respectively. A total of 156 different five-locus haplotypes were
detected, with a total of 121 haplotypes that occurred only once. Six most common five-locus
haplotypes represented 20% of the total. The most common two-, three- and five-locus
haplotypes which occurred 5 or more times are listed in Table 4.
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Table 4. Two (HLA-A, -B), three (HLA-A, -B, -DRB1 and HLA-DRB1, -DQA1, -DQB1) and
five (HLA-A, -B, -DRB1, -DQA1, -DQB1) locus haplotypes with a number of
copies ≥5 in the control group (N=124)
CONTROL GROUP (N=124)
A* B* DRB1* DQA1* DQB1* n %
02 51 - - - 27 10.68
02 18 - - - 14 5.43
24 35 - - - 12 4.93
01 08 - - - 9 3.63
32 40 - - - 8 3.01
23 44 - - - 7 2.82
02 15 - - - 7 2.82
03 18 - - - 6 2.42
02 18 11 - - 15 6.05
02 51 14 - - 10 4.03
01 08 03 - - 7 2.82
24 35 11 - - 6 2.42
23 44 07 - - 6 2.42
- - 11 05:05 03:01 53 21.37
- - 16 01:02 05:02 33 13.26
- - 04 03:01 03:02 19 7.66
- - 03 05:01 02:01 18 7.26
- - 14 01:01 05:03 17 6.85
- - 13 01:03 06:03 16 6.45
- - 07 02:01 02:02 16 6.45
- - 15 01:02 06:02 13 5.24
- - 13 01:02 06:04 10 4.03
- - 01 01:01 05:01 10 4.03
02 18 11 05:05 03:01 16 6.45
02 51 14 01:01 05:03 9 3.63
01 08 03 05:01 02:01 7 2.82
02 51 11 05:05 03:01 6 2.42
23 44 07 02:01 02:02 6 2.42
24 35 11 05:05 03:01 6 2.42
N - number of tested individuals; n - number of observed haplotypes;
% - haplotype frequency, in percentage
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5.1.4. DQA1-DQB1 haplotype frequencies
Twenty-seven different DQA1-DQB1 haplotypes were found in the control group, eight of them
showed a frequency of more than 5%, while 12 haplotypes were found only once. DQA1*05:05-
DQB1*03:01 haplotype showed the highest frequency (24.19%), followed by DQA1*01:02-
DQB1*05:02 and DQA1*03:01-DQB1*03:02 in 14.51% and 7.66% of controls, respectively (see
Table 5).
Table 5. DQA1-DQB1 haplotype frequencies in the control group
CONTROL GROUP (N=124)
DQA1* DQB1* n (%)
01:01 05:01 14 5.64
01:01 05:03 17 6.85
01:02 05:02 36 14.52
01:02 06:02 13 5.24
01:02 06:03 2 0.81
01:02 06:04 10 4.03
01:02 06:09 5 2.02
01:03 06:01 1 0.40
01:03 06:03 16 6.45
01:03 06:09 1 0.40
01:04 05:03 1 0.40
02:01 02:02 16 6.45
02:01 03:03 1 0.40
03:01 03:01 3 1.21
03:01 03:02 19 7.66
03:02 03:01 2 0.81
03:02 03:02 1 0.40
03:03 02:02 1 0.40
03:03 03:01 1 0.40
03:03 03:03 1 0.40
03:03 04:02 1 0.40
04:01 04:02 5 2.02
05:01 02:01 18 7.26
05:01 02:02 1 0.40
05:05 02:02 1 0.40
05:05 03:01 60 24.19
05:05 03:04 1 0.40
N - number of tested individuals; n - number of observed haplotypes;
% - haplotype frequency, in percentage
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5.1.5. DQ heterodimer type frequency
DQ heterodimer type frequency in controls is presented in Table 6. A total of 12 different
heterodimer types were found, four occurring only once. The most frequent heterodimer types
found in controls were DQ5.1 and DQ6.1, with frequency of 27.42 % and 19.35%, respectively.
At less extended frequency were DQ2.5 and DQ8.3, both with the same frequency of 8.06%,
followed by DQ2.2, with a frequency of 6.45%.
Table 6. Analysis of DQ heterodimer type frequency in the control group
N - number of tested individuals; n - number of observed heterodimer types;
HD – heterodimer; % - HD type frequency, in percentage
CONTROL GROUP (N=124)
DQ HD TYPE n %
DQ2.2 16 6.45
DQ2.3 1 0.40
DQ2.5 20 8.06
DQ4.3 1 0.40
DQ4.4 5 2.01
DQ5.1 68 27.42
DQ6.1 48 19.35
DQ7.3 6 2.41
DQ7.5 61 24.6
DQ8.3 20 8.06
DQ9.2 1 0.40
DQ9.3 1 1.40
DQ9.3 1 0.40
34
5.1.6. Heterodimer genotype frequencies
The detailed heterodimer genotype distribution, as defined by the combination of HLA DQA1
and DQB1 genes and alleles in the individual genotype, is presented in Table 7. The presence of
HLA-DQ2.5/DQ8/DQ2.2 genotypes was categorized according to the presence of CD
predisposing HLA alleles, as described in section Methods.
Table 7. CD predisposing HLA-DQ heterodimer genotype in the control group
N - number of tested individuals; n - number of individuals positive for HD genotype;
HD – heterodimer; % - HD genotype frequency, in percentage
note: definition of heterodimer types is presented in section Methods
CONTROL GROUP (N=124)
DQ HD GENOTYPE n %
DQ2.5/X 19 15.32
DQ2.5cis 17 13.71
DQ2.5trans 2 1.61
DQ8/X 17 13.71
DQ2.2/X 8 6.45
DQ2.5/DQ2.5 0 0
DQ8/DQ8 1 0.81
DQ2.2/DQ2.2 2 1.61
DQ2.5/DQ8 1 0.81
DQ2.5/DQ2.2 2 1.61
DQ8/DQ2.2 0 0.00
HD POSITIVE DQ2.5/DQ8/DQ2.2 50 40.32
HD NEGATIVE X/X 74 59.68
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In the whole data set, 40.32 % of healthy controls were positive and 59.68 % were negative for at
least one of the predisposing CD heterodimer genotype, i.e. HLA-DQ2.5/DQ8/DQ2.2 positive or
negative (see Figure 5). The most prevalent HD positive genotype was DQ2.5/X with a frequency
over 15.32%. Positivity for one copy of DQ2.5 heterodimer was more prevalent in cis position
than in trans position. On the other hand, none of the controls was homozygous for DQ2.5, i.e.
having genotype positive for two copies of DQ2.5 heterodimer. Second most prevalent genotype
was single copy DQ8 genotype (DQ8/X) which was present in almost 13.71% of healthy children.
Figure 5. Predisposing CD heterodimer genotype distribution in controls
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5.2. Confirmed celiac disease cases - index cases
5.2.1. General aspects
In the group of confirmed CD patients, consisting of 60 children, the gender distribution showed
a female predominance, with an overall female to male ratio of 1.9:1 (see Figure 6).
Figure 6. Gender distribution in CD patients
Patients’ mean age at diagnosis was 5.5 years (SD±3.31), ranged from 17 months to 18 years.
Mean age at CD onset was 3.3 years old (SD±2.02) while the delay from first symptoms
indicative of CD to diagnosis was 6 months to 10 years, with a median delay of 2.4 years
(SD±2.11).
Forty-one children had been breastfed as infants, while 34 of them were exclusively breastfed for
the first 6 months. The overall mean duration of breastfeeding was 10.2 month. Among the cases,
non-breastfed children (n=19 or 32 %) had earlier onset of symptom, at median age of 1.9 years
as compared to the breastfeed group (41 or 68 %) with a median age of 3.7 years (p=0.002), as
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well as earlier diagnosis (p=0.001). Anyway, there was no significant difference on delay to
diagnosis between breastfed and non-breastfed children (p=0.8).
Mean age at gluten introduction was 5.2 month, one third of cases started gluten earlier than 5
months of ages. This group of children had earlier onset of symptoms and earlier diagnosis
compared to those that started gluten ingestion after 5 months of ages, p<0.001. Table 8
enumerates the descriptive characteristics of all 60 cases.
Table 8. The descriptive characteristics of CD patients
Characteristic N (%) P value
Gender
Female 39 (65%)
Male 21 (35%)
Mean age at diagnosis (y) 5.5
Mean age at CD onset (y) and gluten introduction,
<5 mo / >5 mo
2.3/3.6 0.017
Breastfeeding
Breastfeeding, yes/no 41/19
Mean duration of breastfeed (mo) 10.2
Mean age at gluten introduction (mo), Bf yes/no 5.6/4.6 0.076
Mean age at CD onset (y), Bf yes/no 3.7/1.9 0.002
Mean age at diagnosis of CD (y), Bf yes/no 6.1/4.1 0.001
N - number of tested individuals; mo - months, y - years; Bf - breastfeed
Classical CD occurred in 78% of the cases (mean age at diagnosis 4.5 ± 2.36 years), while the
non–classical form was found in 22% (mean age at diagnosis 9.2 ± 3.69 years) (p<0.0001). Mean
age at symptom onset differed significantly between the classical and non-classical forms of CD
(p<0.0001). Furthermore, there were also significant differences according to age at diagnosis
and the delay to diagnosis (p <0.001 for both) (see Table 9).
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Table 9. Classic versus non-classic characteristic of CD patients
Characteristics
N (%) Mean age
at CD diagnosis
(y)
Mean age at
CD onset
(y)
Mean
Delay
(y)
Total Celiac disease 60 (100) 5.5 3.2 2.4
Classic CD 47 (78) 4.5 2.8 1.9
Non- classic CD 13 (22) 9.2 4.8 4.3
P value < 0.0001 < 0.0001 < 0.0001 < 0.0001
N - number of tested individuals, %-percentage, y-years
5.2.2. Clinical symptomatology
According to age groups, CD diagnoses were as follows: 60% in the first 5 years of life, 30% age
6 -10 years, and 10% 11-18 years age group.
The clinical presentation pattern showed different distributions among the three age groups
(p<0.001). All signs and symptoms were significantly more prevalent in children diagnosed in
the first 5 years of life (p<0.001) except for dental enamel defects, decreased bone mineralization
and arthritis/arthralgia. Gastrointestinal symptoms were more prevalent in the youngest age group
(1–5 years old) at 94%, whereas, the prevalence of these symptoms decreased gradually with age,
presenting in 66% of the second age group and in only 16% of the third age group (see Figure 7).
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Figure 7. CD forms distribution according to age groups
The most common presenting symptoms in all 60-incident cases were anorexia and anaemia,
which were found in 82% and 75% of all cases, respectively. No significant differences were
noticed between the three age groups in the frequency of iron deficiency (p=0.308), but it was
present in all (100%) children from the third age group. The most frequent symptom in children
ages 6 to 10 was abdominal pain in 16 (89%) cases, which was also prevalent in two other age
groups (p=0.898). More than two third of the patients exhibited a normal nutritional status,
including most patients with classical form. Failure to thrive (FTT) and/or short stature (SS) were
present in 16 and 18 cases, 27% and 30%, respectively. There were significant differences
(p<0.001) between the study groups regarding FTT with or without short stature. It is noteworthy
that a large number of young-age group (1-5), namely 94%, with classical malabsorption had no
malnutrition at diagnosis; however, 50% of the children 6-10 years and 83% from the third age
group were undernourished at diagnosis. Other extra-intestinal symptoms, rare, but mostly
manifested in third age group, were arthritis, decreased bone mineralization and neuropathy.
Three girls (50%) from the age group 11-18 years old had delayed puberty. The CD symptoms at
presentation according to age groups are shown in Table 10.
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Table 10. Clinical presentation of patients with CD according to age groups
Symptoms at
Presentation
1-5y
N- 36 (60 %)
6-10y
N- 18 (30 %)
11-18y
N- 6 (10 %)
Total
N- 60 (100 %)
P- value
Gastrointestinal
Diarrhea 34 (94 %) 12 (66 %) 1 (16 %) 47 (78 %) <0.001
Distended abdomen 34 (94 %) 12 (66 %) 1 (16 %) 47 (78 %) <0.001
Abdominal pain 22 (61 %) 16 (89 %) 4 (66 %) 42 (70 %) 0.898
Vomiting 21 (58 %) 6 (33 %) 1 (16 %) 28 (47 %) 0.086
Constipation 3 (8 %) 6 (33 %) 4 (66 %) 13 (22 %) 0.004
Anorexia 30 (83 %) 14 (77 %) 5 (83 %) 49 (82 %) 0.892
Extraintestinal
Weight loss 34 (94 %) 12 (66 %) 1 (16 %) 47 (78 %) <0.001
Failure to thrive 2 (5 %) 9 (50 %) 5 (83 %) 16 (27 %) <0.001
Short stature 3 (8 %) 10 (55 %) 5 (83 %) 18 (30 %) <0.004
Anemia 26 (72 %) 13 (72 %) 6 (100 %) 45 (75 %) 0.308
Irritability 16 (44 %) 9 (50 %) 5 (83 %) 30 (50 %) 0.073
Chronic fatigue 7 (20 %) 13 (72 %) 6 (100 %) 26 (43 %) <0.001
Delayed puberty 0 0 3 (50 %) 3 (5 %) <0.001
Neuropathy 0 1 (6 %) 2 (33 %) 3 (5 %) <0.001
Decreased bone
mineralization
1 (3 %) 2 (10 %) 2 (33 %) 5 (8 %) 0.035
dental enamel defects 3 (8 %) 3 (16 %) 1 (16 %) 6 (10 %) 0.438
Arthritis/arthralgia 1 (3 %) 2 (10 %) 2 (33 %) 5 (8 %) 0.028
N- number of tested individuals, %-percentage, y-age in years
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Among others, personal and family history were investigated and the presence of any associated
conditions was reported. Positive family history for CD was present for 7 children (12%), with
first-degree history (siblings) in 4 children and second- or third-degree history in 3 children.
Associated diseases were found in 11 patients: DMT1 in three cases (5%) while autoimmune
thyroid disease, Down syndrome, Turner syndrome, and cystic fibrosis in one case each. One
patient was IgA immune-deficient (see Table 11).
Table 11. Family history and associated disease frequency
Characteristics N %
Positive family history of CD 7 12
First degree 4 7
Second degree 3 5
Associated conditions 11 18
Type 1 diabetes 3 5
Thyroid disease 1 1.6
Bone disease 2 3.3
Down syndrom, 1 1.6
Turner syndrome 1 1.6
Fibrosis cystica 1 1.6
Radial aplasia 1 1.6
Hemiplegia 1 1.6
IgA Immune-deficiencies 1 1.6
N - number of tested individuals, %-percentage
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5.2.3. Diagnostic tool
All diagnostic tools performed in confirm CD patients are presented in Figure 8.
Figure 8. Algorithm for CD diagnosis conducted in 60 confirmed CD children. Anti TG2- tissue
transglutaminase 2, EMA-endomysial antibody, SBB-small bowel biopsies, HLA done-
heterodimer DQ2.5, DQ2.2, DQ8 testing, Not Done-not tested;
*- One patient IgA deficient (IgG- immunoglobulin G class anti TG2 and EMA positive)
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5.2.3.1. Biochemical parameters
Table 12 represent the biochemical parameters of confirmed CD patients. All 60 patients were
tested for IgA anti-TG2, 59 (98.4%) resulted positive, while 51 (86%) of them had titres levels
>10 times ULN. Fifty-seven patients (95%) were tested for IgA anti DGP, and 98% of them were
positive. IgA EMA was performed in eighty-seven percent of patients (n-52), it resulted positive
for 51 of them. In eight patients that were not tested for EMA, CD diagnosis was done according
to their positive SBB. One patient with IgA deficiency, belonging to the first age group (1-5) was
positive for IgG EMA and anti TG2 (>10 times ULN).
Table 12. Biochemical parameters performed in confirmed CD patients
Test N (%) Positive Negative
IgA anti-TG2 60 (100%) 59 (98.4%)
51 (86%)>10NUL
8 (14%)<10NUL
1 (1.6%) *
IgA anti DGP 57 (95%) 56 (98.2%) 1 (1.8%)*
IgA –EMA 52 (87%) 51 (98.0%) 1 (2%)*
IgA anti TG2- imunoglobuline A anti tissue transglutaminase 2, DGP- deaminated gliadin
peptide, EMA-anti endomysial antibody, SBB-small bowel biopsies,
*- One patient IgA deficient (IgG anti TG2 and EMA positive).
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5.2.3.2. Small Bowell Biopsies
The majority of 24 performed biopsies were significant for severe enteropathy (90%, P<0.001),
regardless of age, sex, or presenting symptoms. Histological examination showed villous atrophy
as follows: 33% Marsh IIIa, 20% Marsh IIIb, and 38% Marsh IIIc. Increased intraepithelial
lymphocytes with crypt hyperplasia (Marsh II) were found in 2 patients (see Table 13).
Table 13. Histopathological results of performed biopsies
Images Stages * n (%)
Type 0 Pre-infiltrative mucosa. Normal stage
of the intestinal mucosa.
0
Type I Increased number of the non - mitotic
intraepithelial lymphocytes (IELs), more than
30 per 100 enterocytes. Normal mucosal
architecture.
0
Type II Increased IEL infiltration, crypt
hyperplasia (increase in crypt depth without a
reduction in villous height).
2 (8 %)
Type IIIa Classical CD lesion with partial
villous atrophy
8 (33%)
Type IIIb Classical CD lesion with subtotal
villous atrophy
5 (20%)
Type IIIc Classical CD lesion with total
villous atrophy
9 (38%)
*Grading according to the revised Marsh-Oberhuber classification, as Marsh I to III,
IELs - intraepithelial lymphocytes.
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5.2.3.3. Genetics
5.2.3.3.1 HLA-A, B and DRB1 gene frequencies
The estimated gene frequencies for the HLA-A, -B and –DRB1 loci studied in 60 confirmed CD
patients, are shown in Table 14. Fifteen HLA-A, 21 HLA-B and 12 HLA-DRB1 different genes
were detected in the patient group. At HLA-A locus, the most frequent gene, A*01 was present
with a frequency of 27%, while A*02 was also present with a frequency greater than 20%. These
two genes together with A*03 as the third most common gene (10%) together represent more
than half (57%) of all HLA-A genes detected. The less frequent genes, present in only one patient,
were A*30, *31 and A*69 while four genes were not detected, HLA-A*34, A*36, A*66 and
A*80.
At HLA-B locus the most prevalent gene was B*08 with a frequency of 29% while only one gene,
B*51, had a frequency greater than 10%. Five different genes were present in only one patient
(B*37, *47, *53, *55, *58) and 15 HLA-B genes were not found in patients (B*41, *42, *45, *46,
*48, *54, *56, *57, *59, *67, *73, *78, *81, *82 and *83).
Out of 12 HLA-DRB1 genes detected, the most frequent was HLA-DRB1*03 (38.33%) followed
by HLA-DRB1*07 (17.50%) and HLA-DRB1*11 (13.33%), representing jointly 69% of the total.
DRB1*08, *10, *12 were the less frequent genes, detected in only one patient. Gene DRB1*09
was not detected in the patient group.
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Table 14. HLA-A, B and DRB1 gene frequencies in the patient group
PATIENT GROUP (N=60)
A* n GF (%) IF (%) B* n GF (%) IF (%) DRB1* n GF (%) IF (%)
01 32 26.67 53 07 10 8.33 12 01 3 2.50 5
02 26 21.67 43 08 35 29.17 11 03 46 38.33 77
03 12 10.00 20 13 5 4.17 5 04 7 5.83 11
11 4 3.33 7 14 3 2.50 3 07 21 17.50 35
23 7 5.83 12 15 2 1.67 7 08 1 0.83 2
24 9 7.50 15 18 8 6.67 26 10 1 0.83 2
25 2 1.67 3 27 3 2.50 5 11 16 13.33 27
26 4 3.33 7 35 4 3.33 25 12 1 0.83 2
29 3 2.50 5 37 1 0.83 4 13 6 5.00 10
30 1 0.83 2 38 6 5.00 12 14 3 2.50 5
31 1 0.83 2 39 2 1.67 5 15 8 6.67 13
32 8 6.67 13 40 3 2.50 10 16 7 5.83 11
33 2 1.67 3 44 10 8.33 3
68 8 6.67 13 47 1 0.83 11
69 1 0.83 2 49 2 1.67 3
50 7 5.83 6
51 13 10.83 1
52 2 1.67 32
53 1 0.83 3
55 1 0.83 3
58 1 0.83 3
N - number of tested individuals; n - number of genes detected;
GF % - gene frequency, in percentage; IF % - individuals positive for the gene, in percentage
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5.2.3.3.2. HLA-DQA1 and DQB1 allele frequencies
The HLA-DQA1 and HLA-DQB1 allele frequencies of 60 examined confirmed CD patients are
listed in Table 15.
Within DQA1 alleles, out of eleven detected, the most prevalent one was DQA1*05:01 (40.00%),
while two alleles had a frequency higher than 10%: DQA1*02:01 (17.50%) and DQA1*01:02
(13.33%), representing jointly 70 % of the total.
Twelve DQB1 alleles were identified. DQB1*02:01 was the most frequent one (40.00%),
followed by two alleles with a frequency higher than 10%: DQB1*02:02 (18.33%) and
DQB1*03:01 (14.17 %), together representing jointly 73% of the total.
The less frequent ones were DQA1*03:02, DQA1*03:03, DQA1*04:01, DQB1*04:02 and
DQB1*06:01 which were present in only one patient.
Table 15. HLA-DQA1, -DQB1 allele frequencies in the patient group
PATIENT GROUP (N=60)
DQA1* n AF (%) IF (%) DQB1* n AF (%) IF (%)
01:01 7 5.83 12 02:01 48 40.00 80
01:02 16 13.33 2 02:02 22 18.33 37
01:03 4 3.33 7 03:01 17 14.17 28
02:01 21 17.50 35 03:02 5 4.17 8
03:01 5 4.17 8 04:02 1 0.83 2
03:02 1 0.83 2 05:01 4 3.33 7
03:03 1 0.83 2 05:02 8 6.67 13
04:01 1 0.83 2 05:03 3 2.50 5
05:01 48 40.00 80 06:01 1 0.83 2
05:05 16 13.33 26 06:02 5 4.17 8
06:03 4 3.33 7
06:04 2 1.67 3
N - number of tested individuals; n - number of observed alleles;
AF % - allele frequency, in percentage; IF % - individuals positive for the allele, in percentage
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5.2.3.3.3. Two-, three- and five-locus haplotype frequencies
HLA-A,-B two-locus haplotype analysis revealed HLA-A*01-B*08 as the most frequent one
found at a frequency of 22.44%, followed by HLA-A*02-B*51 and HLA-A*02-B*50, with a
frequency of 7.50% and 4.97 %, respectively.
A total of 56 different haplotypes were detected, with 37 haplotypes present only once, while 6
different haplotypes occurred 4 or more times, representing 45% of a total number of haplotypes
in controls.
HLA-A,-B, DRB1 three-locus haplotype analysis revealed 68 different haplotypes, among which
51 haplotypes occured only once. Five haplotypes which were present 4 or more times and
together represented 38% of all haplotypes. The most frequent one was HLA-A*01-B*08-
DRB1*03 (22.50%).
HLA-DRB1-DQA1-DQB1 three locus haplotype analysis showed that DRB1*03-DQA1*05:01-
DQB1*02:01 and HLA-DRB1*07-DQA1*02:01-DQB1*02:02 were the most frequent
haplotypes, with a frequency of 38.33% and 17.50%, respectively. A total of 20 different
haplotypes were detected, with 9 haplotypes present only once.
The most frequent five locus haplotypes was found to be HLA-A *01-B*08-DRB1*03-
DQA1*05:01-DQB1*02:01 followed by HLA-A*02-B*50-DRB1*07-DQA1*02:01-
DQB1*02:02 and HLA-A*02-B*51-DRB1*11-DQA1*02:0-DQB1*02:02 with a frequency of
4.17% each
A total of 71 different five locus haplotypes were detected, with a total of 55 haplotypes that
occurred only once. Four most common five locus haplotypes represented 34% of the total. The
most common two, three and five locus haplotypes which occurred more than 5 times are listed
in Table 16.
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Table 16. Two (HLA-A-B), three (HLA-A-B-DRB1 and HLA-DRB1-DQA1-DQB1) and five
(HLA-A-B-DRB1-DQA1-DQB1) locus haplotypes with a number of copies ≥4 in
the patient group (N=60)
PATIENT GROUP (N=60)
A* B* DRB1* DQA1* DQB1* n %
01 08 - - - 27 22.45
02 51 - - - 9 7.50
02 50 - - - 6 4.99
68 44 - - - 5 4.17
03 07 - - - 4 3.33
24 07 - - - 4 3.33
01 08 03 - - 27 22.50
02 50 07 - - 5 4.17
68 44 07 - - 5 4.17
02 51 11 - - 5 4.17
24 07 15 - - 4 3.33
- - 03 05:01 02:01 46 38.33
- - 07 02:01 02:02 21 17.50
- - 11 05:05 03:01 14 11.67
- - 16 01:02 05:02 7 5.83
- - 04 03:01 03:02 5 4.17
- - 15 01:02 06:02 5 4.17
01 08 03 05:01 02:01 27 22.50
02 50 07 02:01 02:02 5 4.17
02 51 11 05:05 03:01 5 4.17
68 44 07 02:01 02:02 4 3.33
N - number of tested individuals; n - number of observed haplotypes;
% - haplotype frequency, in percentage
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5.2.3.3.4. DQA1-DQB1 haplotype frequencies
Sixteen different DQA1-DQB1 haplotypes were found in confirmed CD patients, four of them
showed a frequency more than 5%, representing jointly 76.16% of the total. Six haplotypes were
present only once. DQA1*05:01-DQB1*02:01 haplotype showed the highest frequency (40.00%),
followed by DQA1*02:01-DQB1*02:02 and DQA1*05:05-DQB1*03:01 in 17.50% and 12.50%
of patients, respectively (see Table 17).
Table 17. DQA1-DQB1 haplotype frequencies in the patient group
PATIENT GROUP (N=60)
DQA1* DQB1* n (%)
01:01 05:01 4 3.33
01:01 05:03 3 2.50
01:02 05:02 8 6.67
01:02 06:02 5 4.17
01:02 06:03 1 0.83
01:02 06:04 2 1.67
01:03 06:01 1 0.83
01:03 06:03 3 2.50
02:01 02:02 21 17.05
03:01 03:02 5 4.17
03:02 03:01 1 0.83
03:03 03:01 1 0.83
04:01 04:02 1 0.83
05:01 02:01 48 40.00
05:05 02:02 1 0.83
05:05 03:01 15 12.50
N - number of tested individuals; n - number of observed haplotypes;
% - haplotype frequency, in percentage
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5.2.3.3.5. DQ heterodimer type frequency
DQ heterodimer type frequency in sixty confirmed CD patients is presented in Table 18. A total
of 8 different heterodimer types were found, one occurring only once. The most frequent
heterodimer types found in patients were DQ2.5 and DQ2.2 with frequency of 40.83% and
17.50%, respectively. At less extended frequency were DQ5.1 and DQ7.5, both with the same
frequency of 12.50%, followed by DQ6.1 heterodimer, with a frequency of 10.00%.
Table 18. Analysis of DQ heterodimer type frequency in the patient group
PATIENT GROUP (N=60)
DQ HD TYPE n %
DQ2.2 21 17.50
DQ2.5 49 40.83
DQ4.4 1 0.83
DQ5.1 15 12.50
DQ6.1 12 10.00
DQ7.3 2 1.67
DQ7.5 15 12.50
DQ8.3 5 4.17
N - number of tested individuals; HD – heterodimer; n - number of observed heterodimer types;
% - HD type frequency, in percentage
note: definition of heterodimer types is presented in section Methods
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5.2.3.3.6. Heterodimer genotype frequencies
The detailed heterodimer genotype distribution, as defined by the combination of HLA DQA1
and DQB1 genes and alleles in the individual genotype, is presented in Table 19. The presence of
HLA-DQ2.5/DQ8/DQ2.2 genotypes was categorized according to the presence of CD
predisposing HLA alleles.
In the whole data set, 95 % of patients were positive and 5 % were negative for at least one of the
predisposing CD heterodimer genotype, i.e. HLA-DQ2.5/DQ8/DQ2.2 positive or negative (see
Figure 9). The most prevalent HD positive genotype was DQ2.5/X with a frequency of 58%.
Positivity for one copy of DQ2.5 heterodimer was more prevalent in cis position than in trans
position. Three patients were homozygous for DQ2.5, i.e. having genotype positive for two
copies of DQ2.5 heterodimer. Second most prevalent genotype was DQ2.5/DQ2.2 genotype
which was present in 20% of patients.
Table 19. CD predisposing HLA-DQ heterodimer genotype in the patient group
N - number of tested individuals; n - number of individuals positive for HD genotype; HD –
heterodimer; % - HD genotype frequency, in percentage
PATIENT GROUP (N=60)
DQ HD GENOTYPE n %
DQ2.5/X 35 58.33
DQ2.5cis 28 46.66
DQ2.5trans 7 11.66
DQ8/X 2 3.33
DQ2.2/X 2 3.33
DQ2.5/DQ2.5 3 5.00
DQ8/DQ8 0 0.00
DQ2.2/DQ2.2 0 0.00
DQ2.5/DQ8 3 5.00
DQ2.5/DQ2.2 12 20.00
DQ8/DQ2.2 0 0.00
HD POSITIVE DQ2.5/DQ8/DQ2.2 57 95.00
HD NEGATIVE X/X 3 5.00
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Figure 9. Predisposing CD heterodimer distribution in patients
5.3. Comparison of HLA-A, -B -DRB1, - DQA1 and –DQB1 allele and haplotype
polymorphism between patients and healthy controls
5.3.1 HLA alleles and haplotypes with increased frequency in patients
Table 20 enumerates HLA alleles and haplotypes, which were found out to have statistically
significant increased frequency in patients in comparison to controls. The most frequent HLA-A
gene detected in patients group was HLA-A*01, with significant difference when comparing with
control group (p=0.0001). At HLA-B locus, two genes were present with increased frequency in
patients, B*08 (p<0.001) and B *50 (p=0.011).
As expected, the HLA-DRB1*03 and DRB1*07 alleles were more prevalent in patients in
comparison to controls, with high statistically significant difference, p<0.0001 and p=0.002,
respectively. Concerning the HLA-DQ alleles distribution, HLA-DQA1*05:01 and DQA1*02:01
results to be significantly more prevalent in patients (p<0.0001 and p=0.002, respectively), while
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DQB1*02:01 and DQB1*02:02 alleles were more expressed in patients in comparison to controls
(p<0.0001 and p=0.003, respectively).
Two-, three- and five-locus haplotype analysis also revealed several haplotypes with statistically
significant increased frequency in patients.
The two locus haplotype analysis including HLA class I genes, revealed HLA-A*01-B*08
haplotype, to be more prevalent in patients in comparison to controls (22.44%, 3.62%
respectively, p<0.0001), followed by HLA-A*02-B*50 to be expressed in 4.97% of patients and
in 0.40 % of controls, respectively (p=0.018). On the other hand, the two locus haplotype analysis
including class II genes at HLA-DQ locus showed that HLA-DQA1*05:01-DQB1*02:01 and
DQA1*02:01-DQB1*02:02 haplotype were significantly more prevalent in patients in
comparison to controls, p<0.0001 and p=0.001, respectively.
Three-locus haplotype analysis, including class I HLA-A and B locus and class II HLA-DRB1
locus, showed that HLA-A*01-B*08-DRB1*03, results to be much more present in patients
(22.50%) in comparison to controls (2.82 %), p<0.0001. The significant difference was also
detected for haplotype HLA-A*02-B*50 -DRB1*07, found in 4.16% of patients and 0.040 % of
controls, p=0.031.
Three locus haplotypes analysis comprising class II HLA-DRB1, DQA1 and DQB1 loci, revealed
that HLA-DRB1*03-DQA1*05:01-DQB1*02:01 and HLA-DRB1*07-DQA1*02:01-
DQB1*02:02 haplotypes were significantly more prevalent in patients, p<0.0001 and p=0.001,
respectively.
Finally, five locus analysis, encompassing all loci studied in this work, showed that two extended
haplotypes were found in increased frequency in patients in comparison with controls. HLA-
A*01-B*08-DRB1*03-DQA1*05:01-DQB1*02:01 was the most frequent haplotype (22.50%) in
patients which was present in only 2.82% in controls (p<0.0001). The HLA-A*02-B*50-
DRB1*07-DQA1*02:01-DQB1*02:02 was the second haplotype which was present with
statistically significant higher frequency in patients, found in 4.2% of patients and 0.40% of
controls (p=0.031).
For HLA-A*68-B*44, A*68-B*44-DRB1*07 and A*68-B*44-DRB1*07- DQA1*02:01-
DQB1*02:02 haplotype, statistically significant p value was found in comparison to controls, but
the calculation of OD and CI was not applicable due to 0% frequency in controls.
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Table 20. HLA genes, alleles and haplotypes with statistically significant increased frequency in
patients
N - number of tested individuals; % - gene/allele/haplotype frequency in percentage, p – p value;
OD - odds ratio; CI - confidence interval; na – not applicable
PATIENTS
N=60
CONTROLS
N=124
A* B* DRB1* DQA1* DQB1* % % p OD (95% CI)
01 - - - - 26.67 10.48 0.0001 3.104 (1.750-5.509)
- 08 - - - 29.17 5.65 <0.0001 6.882 (3.530-13.418)
- 50 - - - 5.83 0.40 0.011 15.300 (1.860-125.842)
- - 03 - - 38.33 7.26 <0.0001 7.942 (4.339-14.539)
- - 07 - - 17.50 6.85 0.002 2.882 (1.458-5.697)
- - - 02:01 - 17.50 6.85 0.002 2.882 (1.458-5.697)
- - - 05:01 - 40.00 7.66 <0.0001 8.035 (4.438-14.547)
- - - - 02:01 40.00 7.26 <0.0001 8.518 (4.661-15.567)
- - - - 02:02 18.33 7.66 0.002 2.823 (1.463-5.449)
01 08 - - - 22.50 3.63 <0.0001 7.709 (3.493-17.013)
02 50 - - - 4.98 0.40 0.018 13.00 (1.547-09.244)
68 44 - - - 3.33 0.0 0.048 na
01 08 03 - - 22.50 2.82 <0.0001 9.995 (4.208-23.740)
02 50 07 - - 4.17 0.40 0.0311 10.739 (1.240-92.975)
68 44 07 - - 4.17 0.0 0.003 na
02:01 02:02 17.50 6.45 0.001 3.075 (1.540-6.142)
05:01 02:01 40.00 7.26 <0.0001 8.518 (4.661-15.567)
- - 03 05:01 02:01 38.33 7.26 <0.0001 7.942 (4.339-14.539)
- - 07 02:01 02:02 17.50 6.45 0.001 3.075 (1.540-6.142)
01 08 03 05:01 02:01 22.50 2.82 <0.0001 9.995 (4.208-23.740)
02 50 07 02:01 02:02 4.17 0.40 0.031 10.739 (1.240-92.975)
68 44 07 02:01 02:02 3.33 0.0 0.048 na
56
5.3.2. HLA alleles and haplotypes with decreased frequency in patients
Table 21 enumerates HLA alleles and haplotypes, which were found out to be statistically
significant decreased in patients in comparisons to controls.
Regarding HLA-A and HLA-B locus, A*02, as the most frequent gene at HLA-A locus, and
B*35, as the second most frequent gene at HLA-B locus, in healthy control individuals were
more frequent than in patients. HLA-A*02 was present in 32.66 % of controls and 21.67%
patients (p=0.031), while HLA-B*35 allele was present in 12.50% of controls and 3.33% of
patients (p=0.009). The top three most frequent HLA-DRB1 genes in controls, DRB1*11,
DRB1*13 and DRB1*16 were also more prevalent than in patients (p=0.046, p=0.010 and
p=0.029, respectively).
Concerning to HLA-DQA1 and DQB1 gene distribution, the top two most frequent genes in
controls at each of two loci, DQA1*01:02, DQA1*05:05 and DQB1*03:01, DQB1*05:02 were
less expressed in patients than controls, p=0.004, 0.011, 0.008 and 0.034, respectively.
Two, three and five locus haplotype analysis also revealed several haplotypes with statistically
significant decreased frequency in patients.
The two-locus haplotype analysis including class II genes at HLA-DQ locus revealed that
DQA1*01:02-DQB1*05:02 and DQA1*05:05-DQB1*03:01 haplotype were significantly more
prevalent in controls than patients, p=0.034 and 0.010, respectively.
Three locus haplotypes analysis comprising class II HLA-DRB1, -DQA1 and -DQB1 loci,
showed that HLA-DRB1*11-DQA1*05:05-DQB1*03:01 and HLA-DRB1*16-DQA1*01:02-
DQB1*05:02 haplotypes were more prevalent in control group, p=0.015 and 0.020, respectively.
For two different HLA-A and B haplotypes (A*02-B*18 and HLA-A*24-B*35) as well as two
different A-B-DR haplotypes (HLA-A*02-B*18-DRB1*11 and HLA-A*02-B*51-DRB1*14),
statistically significant p value was found in comparison to controls, but the calculation of OD
and CI was not applicable due to 0% frequency in patients. Finally, there was no five-locus
haplotype with statistically significant increased frequency in controls.
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Table 21. HLA genes, alleles and haplotypes with statistically significant decreased frequency
in patients
N - number of tested individuals; % - gene/allele/haplotype frequency in percentage, p – p value;
OD - odds ratio; CI - confidence interval; na – not applicable
PATIENTS
N=60
CONTROLS
N=124
A* B* DRB1* DQA1* DQB1* % % p OD (95% CI)
02 - - - - 21.67 32.66 0.031 0.570 (0.342-0.948)
- 35 - - - 3.33 12.50 0.009 0.241 (0.083-0.700)
- - 11 - - 13.33 22.18 0.046 0.539 (0.294-0.989)
- - 13 - - 5.00 14.52 0.010 0.309 (0.126-0.757)
- - 16 - - 5.83 13.71 0.004 0.295 (0.128-0.678)
- - - 01:02 - 13.33 26.61 0.005 0.424 (0.233-0.770)
- - - 05:05 - 13.33 25.00 0.011 0.461 (0.253-0.840)
- - - - 03:01 14.17 26.61 0.008 0.455 (0.253-0.817)
- - - - 05:02 6.67 14.52 0.034 0.420 (0.189-0.935)
02 18 - - - 0.0 5.43 0.004 na
24 35 - - - 0.0 4.94 0.008 na
02 18 11 - - 0.0 6.05 0.002 na
02 51 14 - - 0.0 4.03 0.018 na
- - - 01:01 05:03 2.50 6.86 0.088 0.348 (0.100-1.212)
- - - 01:02 05:02 6.67 14.52 0.034 0.420 (0.189-0.935)
- - - 05:05 03:01 12.50 24.19 0.010 0.447 (0.242-0.827)
- - 11 05:05 03:01 11.67 21.37 0.015 0.485 (0.257-0.916)
- - 16 01:02 05:02 5.83 13.26 0.020 0.403 (0.173-0.941)
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5.3.3. HLA-DRB1*04 and DQB1*03:02 (DQ8) alleles and haplotypes in patients and
controls
Statistically significant difference was found between patients and controls for DQB1*03:02
(DQ8) allele, but as this is one of the alleles involved in CD genetic risk, the results are shown in
Table 22. The HLA-DRB1*04 and HLA- DQB1*03:02 alleles, as well as two and three locus
haplotypes comprising DRB1*04 and DQA1*03:01 alleles, were found with almost doubled
frequency in controls, but the difference did not reach statistically significant p value.
Table 22. HLA-DRB1*04 and DQB1*03:02 (DQ8) alleles and haplotypes
in patients and controls
N - number of tested individuals; % - gene/allele/haplotype frequency in percentage, p – p value;
OD - odds ratio; CI - confidence interval
PATIENTS
N=60
CONTROLS
N=124
A* B* DRB1* DQA1* DQB1*
% % p OD (95% CI)
- - 04 - - 5.83 11.29 0.100 0.486 (0.206-1.148)
- - - - 03:02 4.17 8.06 0.171 0.495 (0.181-1.354)
- - - 03:01 03:02 4.17 7.66 0.210 0.524 (0.190-1.439)
- - 04 03:01 03:02 4.17 7.66 0.210 0.524 (0.190-1.439)
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5.3.4. HLA-DQ heterodimer type analysis in patients and controls
The detailed distribution of DQ heterodimer types are presented in Table 23.
In the whole data set, the frequency of DQ 2.5 HD type was almost 41% in CD patients and only
8 % in healthy controls, giving highly significant difference (p<0.0001). DQ2.2 was the second
most prevalent HD type in patients, found at a frequency of 17.50%, and with a statistically
significant higher frequency in comparison with controls (p=0.002).
On the other hand, although detected with a frequency greater than 10% in patients, DQ5.1 and
DQ7.5 HD types were much more prevalent in the controls and the difference was statistically
significant (p=0.002 and p=0.008, respectively). No statistical difference between patients and
controls was observed for DQ8.3 HD type.
Table 23. HLA-DQ heterodimer type frequencies in patients and controls
PATIENTS
N=60
CONTROLS
N=124
DQ HD TYPE % % p OD (95% CI)
DQ2.2 17.50 6.45 0.002 3.075 (1.540-6.142)
DQ2.3 0.00 0.40 0.817 0.684 (0.027-16.930)
DQ2.5 40.83 8.07 <0.0001 7.867 (4.386-14.112)
DQ4.3 0.00 0.40 0.817 0.684 (0.027-16.932)
DQ4.4 0.83 2.02 0.416 0.408 (0.047-3.535)
DQ5.1 12.50 27.42 0.002 0.378 (0.205-0.695)
DQ6.1 10.00 19.35 0.025 0.463 (0.235-0.908)
DQ7.3 1.67 2.42 0.644 0.683 (0.135-3.438)
DQ7.5 12.50 24.60 0.008 0.437 (0.237-0.808)
DQ8.3 4.17 8.07 0.171 0.495 (0.181-1.354)
DQ9.2 0.00 0.40 0.817 0.684 (0.027-16.932)
DQ9.3 0.00 0.40 0.817 0.684 (0.027-16.932)
N - number of tested individuals; HD – heterodimer; % - HD type frequency, in percentage
p – p value; OD - odds ratio; CI - confidence interval
note: definition of heterodimer types is presented in section Methods
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5.3.5. Heterodimer genotype analysis in patients and controls
The detailed distribution of HD genotypes, as defined by the combination of HLA-DQ
haplotypes and HD types is given in Table 24.
The genotype DQ2.5/X was the most prevalent genotype in patients, with more than half of the
patients carrying the single dose of DQ2.5 heterodimer, in either cis (on the same chromosome)
or trans (on different chromosomes) position, with a high significant difference in comparison
with controls. Presence of heterodimer in cis position encountered 80% (25 out of 35) of patients
with a single dose of DQ2.5 heterodimer, with a frequency of 47% in the entire group of patients.
The second most frequent genotype in patients was DQ2.5/DQ2.2 which was present in 20% of
patients and in less than 2% of controls, which was also high statistically significant difference
(p=0.0005).
Presence of DQ2.5 heterodimer in double dose i.e. DQ2.5/DQ2.5 genotype and heterozygous
DQ2.5/DQ8 genotype were present in 5% of patients, each, and without significant difference
with controls. Genotypes positive for DQ8 and DQ2.2 in double dose were not present in patients,
as well as heterozygous DQ8/DQ2.2 genotype, thus the calculation of OD and CI was not
applicable.
In the whole data set, 95.00 % of confirmed CD patients and 40.32% of controls had a genotype
that was positive for at least one of the predisposing DQ heterodimers (HLA-DQ2.5, DQ8,
DQ2.2) (p<0.0001). Only three patients (5%) and at the same time almost 60% of controls were
negative for HLA-DQ2.5, DQ8, DQ2.2 genotype (see Figure 10).
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Table 24. DQ heterodimer genotype frequencies in patients and controls
N - number of tested individuals; HD – heterodimer; % - HD genotype frequency, in percentage
p – p value; OD - odds ratio; CI - confidence interval
note: definition of heterodimer genotypes is presented in section Methods
PATIENTS
N=60
CONTROLS
N=124
DQ HD
GENOTYPE
% % p OR (95%CI)
DQ2.5/DQX 58.33 15.32 <0.0001 7.736 (3.808-15.715)
DQ2.5cis 46.66 13.71 <0.0001 5.507 (2.679-11.320)
DQ2.5trans 11.66 1.61 0.0108 8.056 (1.619-40.074)
DQ8/DQX 3.33 13.71 0.046 0.217 (0.048-0.972)
DQ2.2/DQX 3.33 6.45 0.390 0.500 (0.102-2.430)
DQ2.5/DQ2.5 5.00 0 0.074 N/A
DQ8/DQ8 0.00 0.81 0.814 N/A
DQ2.2/DQ2.2 0.00 1.61 0.562 N/A
DQ2.5/DQ8 5.00 0.81 0.109 6.474 (0.658-63.602)
DQ2.5/DQ2.2 20.00 1.61 0.001 15.250 (3.289-70.693)
DQ8/DQ2.2 0.00 0.00 N/A N/A
HD
POSITIVE
DQ2.5/DQ8/DQ2.2 95.00 40.32 <0.0001 28.120 (8.341-94.790)
HD
NEGATIVE
DQX/DQX 5.00 59.68 <0.0001 0.035 (0.010-0.119)
62
Figure 10. Predisposing CD heterodimer distribution in patients and controls
5.3.6. Sensitivity, specificity, positive predictive value, and negative predictive value
Sensitivity, specificity, positive predictive value, and negative predictive value have been
calculated for HLA factors with extremely high statistically significant difference between
patients and controls (p<0.0001). The results presented in Table 25 show that genotype positive
for at least one of the CD predisposing heterodimers has the highest sensitivity value (95%) and
highest negative predictive value (96%). The highest positive predictive value has been observed
for heterozygous genotype DQ2.5/DQ2.2 (86%), but two extended five-locus haplotypes
HLA-A*01-B*08-DRB1*03-DQA1*05:01-DQB1*02:01 and HLA-A*02-B*50-DRB1*07-
DQA1*02:01-DQB1*02:02 also had high positive predictive value of 79% and 83% respectively.
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Table 25. Sensitivity, specificity, positive predictive value, and negative predictive value for
HLA factors with extremely high statistically significant difference between
patients and controls (p<0.0001)
SENS SPEC PPV NPV
% % % %
HAPLOTYPE
DRB1*03-DQA1*05:01-DQB1*02:01 38 7 72 76
DRB1*07-DQA1*02:01-DQB1*02:02 18 6 57 70
A*01-B*08-DRB1*03-DQA1*05:01-DQB1*02:01 23 3 79 72
A*02-B*50-DRB1*07-DQA1*02:01-DQB1*02:02 4 0.4 83 68
HD TYPE
DQ2.5 41 8 71 76
DQ2.2 18 6 57 70
HD GENOTYPE
DQ2.5/DQX 29 8 65 73
DQ2.5/DQ2.2 10 1 86 69
DQ2.5/DQ8/DQ2.2 POSITIVE 95 40 53 96
DQ2.5/DQ8/DQ2.2 NEGATIVE 5 60 4 47
SENS – sensitivity; SPEC - specificity; PPV – positive predictive value;
NPV – negative predictive value; HD heterodimer
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5.4. Patients clinically suspected (un-confirmed) for CD
5.4.1. Clinical symptomatology
All nine children treated as CD but without complete diagnostic tests, all were symptomatic, and
almost all of them presented with classical tirade of symptoms (chronic diarrhoea, failure to
thrive and distended abdomen) (see Table 26). Seven of them were male while mean age at the
time of diagnosis was 6.2 years.
Table 26. Clinical presentation of patients clinically suspected for CD (N=9)
N - number of tested individuals positive for specific symptom
Symptoms at
presentation N
Gastrointestinal
Diarrhea 8
Distended abdomen 8
Abdominal pain 6
Vomiting 4
Constipation 3
Anorexia 5
Extraintestinal
Weight loss 8
Failure to thrive 4
Short stature 4
Anaemia 9
Irritability 6
Chronic fatigue 5
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5.4.2. Diagnostic tools
5.4.2.1. Biochemical parameters and SBB
All nine children clinically suspected for CD had positive serology for IgA anti-TG2, while IgA
EMA was performed only in 6 cases. Furthermore, none of all nine cases had confirmatory
biopsy (see Table 27).
Table 27. Diagnostic tools on clinically suspected CD patients (n=9)
N - number of tested individuals; Anti-TG2 - anti tissue transglutaminase 2;
EMA-endomysium antibody; SBB-small bowel biopsies
Diagnostic test N
IgA anti-TG2
>10 NUL
<10 NUL
9
6
3
IgA anti-TG2 and EMA 6
IgA anti-TG2, EMA and SBB 0
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5.4.2.2. HLA typing
HLA-A, B, DRB1, DQA1, DQB1 typing was performed for all nine cases; the typing results are
presented for each patient individually in Table 28 since the group was too small for HLA allele
and haplotype frequency analysis. None of the patients was positive for at least one of the three
predisposing CD heterodimers. Nevertheless, five patients were positive for DQA1*05:05 allele
which is a part of DQ2.5 heterodimer while the remaining four patients were completely negative
for the presence of any of DQA1 or DQB1 alleles from DQ2.2, DQ8 or DQ2.2 heterodimer
(heterodimer genotype DQX/DQX).
Table 28 HLA typing results of nine children clinically suspected for CD (n=9)
HLA-A B DRB1 DQA1 DQB1 HD GENOTYPE
Case 1 *02, *24; *35, *38; *12, *16; *01:02, *05:05; *03:01, *05:02 DQX.5/DQX
Case 2 *02, *02; *35, *40; *11, *16; *01:02, *05:05; *03:01, *05:02 DQX.5/DQX
Case 3 *32, *32; *07, *51; *11, *15; *01:02, *05:05; *03:01, *06:02 DQX.5/DQX
Case 4 *01, *68; *18, *37; *11, *16; *03:03, *05:05; *03:01, *03:01 DQX.5/DQX
Case 5 *01, *02; *18, *37; *11, *16; *01:02, *05:05; *03:01, *05:02 DQX.5/DQX
Case 6 *01, *24; *37, *57; *15, *16; *01:02, *01:02; *05:02, *06:02 DQX/DQX
Case 7 *24, *32; *49, *55; *13, *13; *01:02, *01:03; *06:03, *06:04 DQX/DQX
Case 8 *03, *24; *44, *51; *01, *15; *01:01, *01:02; *05:01, *06:02 DQX/DQX
Case 9 *02, *26; *51, *51; *01, *16; *01:01, *01:02; *05:01, *05:02 DQX/DQX
HD - heterodimer
DQX.5/DQX – HD genotype positive for single dose of DQA1*05 allele
DQX/DQX – all other HD genotypes except DQ2.5, DQ2.2 and DQ8
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5.5. CD confirmed patients, siblings of index cases
5.5.1. Clinical symptomatology and diagnostic tool
Three patients were siblings of index case patients and thus were not included in the unrelated
patient group which was used for HLA allele and haplotype polymorphism analysis. All three of
them were diagnosed according to New guidelines ESPGHAN criteria, presenting with classic
clinical symptoms and having positive serology (TG2 titter >10 UNL and positive EMA) (see
Table 29).
Table 29. Characteristics of CD confirmed patients, siblings of index cases
Case Age Symptoms at presentation IgA TG2 IGA-EMA SBB
Case 1 8
diarrhea, distended
abdomen, weight loos
Done
>10 NUL
Done Not done
Case 2 6
diarrhea, distended
abdomen, weight loos
Done
>10 NUL
Done Not done
Case 3 4
diarrhea, distended
abdomen, weight loos
Done
>10 NUL
Done Not done
Anti-TG2-anti tissue transglutaminase 2; EMA-endomysium antibody;
SBB-small bowel biopsies
HLA typing results revealed that that two of them were identical with their index case sibling for
DQ2.5/DQ2.2 genotype and one was haploidentical with index case sibling and positive for
DQ2.5/DQX genotype. Altogether, all three siblings of the index case patients were heterodimer
positive as well (see Table 30).
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Table 30. HLA typing of CD confirmed patients and siblings index cases
A B DRB1 DQA1 DQB1 HD GENOTYPE
Case 1 *02, *02 *07, *50 *03, *07 *02:01, *05:01 *02:01, *02:02 DQ2.5/DQ2.2
ICª *02, *02 *07, *50 *03, *07 *02:01, *05:01 *02:01, *02:02 DQ2.5/DQ2.2
Case 2 *02, *33 *14, *27 *03, *14 *01:01, *05:01 *02:01, *05:03 DQ2.5/DQX
ICª *02, *33 *14, *50 *03, *07 *02:01, *05:01 *02:01, *02:02 DQ2.5/DQ2.2
Case 3 *68, *69 *08, *44 *03, *07 *02:01, *05:01 *02:01, *02:02 DQ2.5/DQ2.2
ICª *68, *69 *08, *44 *03, *07 *02:01, *05:01 *02:01, *02:02 DQ2.5/DQ2.2
ICª - index case
5.6. Healthy siblings of CD index cases - HLA typing
Three healthy children were siblings of index case patients and thus were not included in the
unrelated control group which was used for HLA allele and haplotype polymorphism analysis.
HLA typing results revealed that that one child was completely HLA different with his CD index
case sibling (case 1) while two others were haploidentical with their CD index case siblings (case
2 and 3). Altogether, all three healthy siblings of the index case patients were negative for DQ2.5,
DQ2.2 and DQ8 heterodimers. However, they were positive for DQA1*05:05 allele which is a
part of DQ2.5 heterodimer (heterodimer genotype DQX.5/DQX) (see Table 31).
Table 31. HLA typing results of healthy siblings and celiac disease index case
HD – heterodimer; DQX.5/DQX – HD genotype positive for single dose of DQA1*05 allele
A B DRB1 DQA1 DQB1 HD GENOTPYE
Case 1 *32, *68 *51, *53 *11, *13 *01:02, *05:05 *03:01, *06:09 DQX.5/DQX
IC *01, *03 *08, *38 *03, *13 *01:03, *05:01 *02:01, *06:03 DQ2.5/DQX
Case 2 *32, *68 *15, *18 *11, *15 *01:02, *05:05 *03:01, *06:03 DQX.5/DQX
IC *01, *68 *18, *40 *03, *15 *01:02, *05:01 *02:01, *06:03 DQ2.5/DQX
Case 3 *02, *02 *18, *51 *11, *13 *01:01, *05:05 *03:01, *06:04 DQX.5/DQX
IC *01, *02 *08, *51 *03, *13 *01:02, *05:01 *02:01, *06:04 DQ2.5/DQX
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6. DISCUSSION
To the best of our knowledge, this is the first study performed in Kosovar Albanian children with
CD. The results of our study represent a general picture of celiac disease in paediatric population
with a particular focus on clinical and genetic features.
In our study, the sex distribution showed a female predominance, which is in concordance with
the results of other studies ranging from 1.2:1 to 2.0:1 (106, 107)
Mean age at the time of diagnosis in our studied cases was 5.5 years. Similar results were
reported in several Mediterranean countries, respectively 5-9 years (108, 109). While recent
studies from Sweden, America, and Finland confirm the tendency towards a higher age at
diagnosis, varying from 6.7 to 9.3 years (110-112). Furthermore an upward shift in age at
diagnosis was reported by Namatovu et al. (113) in a Swedish population-based follow-up study,
from 1.1 years, to 4.6 and 6.7 years in the periods 1973-1994, 1995-2003 and 2004-2009,
respectively.
Since the classical form of CD tends to occur at earlier ages, the high prevalence of classical CD
(78%) in our study is not surprising given the young age of our patients. In contrast, only a small
number of patients showed the atypical manifestation, and only a few of these were diagnosed as
belonging to the risk group. Regarding the classical form domination, similar results (70.9%),
were reported from a prospective Spanish study, conducted in 2005–2006 (114). Furthermore,
our finding is in striking contrast to the results of several recent studies from other European
countries, which have shown a decrease in the relative percentage of classical forms of CD. In the
last few years, it has been reported that classical forms represent only 15% to 44% of all cases
(115, 116). Classical form domination of CD cases in our study may be due to the lack of
screening tests and a better awareness among health professionals about atypical or mild
presentations of CD in Kosovo.
Our study showed that breastfed children had older age at the diagnosis of CD but,
simultaneously, the number of children that were not breastfed was small. In addition, the
breastfed children had delayed gluten introduction as compared to the non-breastfed group.
Epidemiological studies suggest that early infant feeding practices may be important
environmental risk factors for the subsequent development of CD. Radlovic et al. (117)
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concluded that mean age at diagnosis was significantly higher in infants, who had been breastfed
at the time of gluten introduction. In addition, Vajpayee et al. (118) conclude that delayed gluten
introduction to infant's diet along with continuing breastfeeding, delays symptomatic CD (103).
While Akobeng et al. (119), in a meta-analysis, concluded that children being breastfed at the
time of gluten introduction had a 52% reduction in the risk of developing CD. All these studies,
like ours, showed that continuing breastfeeding at the time of gluten introduction delayed the
onset of the CD in early crucial years of rapid growth and development. However, it is not clear
whether breastfeeding provides permanent protection, or merely delays the disease.
In our study, 78% of patients had GI symptoms, similar to a study in Switzerland showing 71%
of children with these symptoms over a five-year study period (2001–2006) (120). Earlier studies
from Turkey reported that the classical form was the dominant mode of presentation in 2005,
whereas, the majority of cases changed to the atypical form by 2012 (121, 122).
FTT and short stature were present in approximately 30% of the patients in our study almost
same frequency was reported recently by Nurminen et al. (123) in a Finish study (27%). Even
thought our results differ from a Swedish study (124) conducted in 2000, where FTT was
observed in 11% of children with CD, while a study from Greece showed that children with CD
tend to suffer less often from short stature in recent years, at only 6% (116).
Iron deficiency anaemia was frequently seen in our study population, especially in adolescents.
Multiple diseases can cause anaemia itself, but it can sometimes be the only presenting symptom
of CD. This has been well evaluated by Çekın AH et al. (125) who found a CD prevalence of
8.33% among patients with iron deficiency anaemia of obscure origin, and nearly the same
prevalence (7.8%) was previously reported by Uçardağ et al. (126).
Our results show that IgA antibodies to human TG2 and EMA are reliable as a test for both the
diagnosis and follow-up of childhood CD. Our results for these markers in untreated CD are
similar to those of previous studies using human TG2 with an ELISA test showing both high
sensitivity and specificity (127).
Having a family member with celiac disease significantly increases the chance of celiac disease
in other family members. An estimated pooled prevalence in first-degree relatives is 3-7.5%
varying according to the relationship, gender, and geographic location (128-130). Our results (of
7 % first-degree relatives) are highly in correlation with other authors’ reports (131, 132).
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The association between CD and autoimmune disorders is well-known, due to shared
pathological and genetical mechanisms. There is a possibility of genetic susceptibility to
autoimmunity through IL-2 and IL-21 locus, both inside and outside of HLA region. In our study
in 18% of children CD was associated with other autoimmune disorders, Type 1 diabetes mellitus
(5%) was the leading immunological disorder, which is in accordance with reports from other
studies (5-15%) (133).
We believe that our study is representative of the clinical and epidemiological trends for
paediatric CD in Kosovo, as our hospital is a tertiary centre and thus, covers diverse areas - both
rural and urban ones. Nonetheless, we are aware that our study may have some limitations. First,
it is not feasible to measure the true incidence of CD due to the nature of the disease, its
symptomatology and the lack of a nationwide screening program. Second, a possible limitation
when reporting symptoms inherent in a study of young patients is that they may be less able than
older individuals to describe subjective symptoms, while parents may exaggerate or minimise the
symptomatology.
In the HLA part of this study, the first step was to analyse HLA data in healthy control group, as
no adequate previous HLA data for Kosovar Albanian population has been available. For
example, until the date, there are no reports according to HLA- DQA1 allele distribution in
Albanian population from Kosovo and consequently no data about DQA1-DQB1 haplotype, DQ
heterodimer type and DQ heterodimer genotype frequencies.
Healthy control group consisted of 124 unrelated healthy children, age and sex matched with our
CD patient group. HLA-A, B and DRB1 gene frequencies and DQA1 and DQB1 allele
frequencies have been analysed, as well as haplotype frequencies. The results obtained were
compared with the results from two studies by Sulcebe (134, 135). There was no difference in
HLA-A, B, DRB1 and DQB1 allele frequencies, neither between our control group and group of
120 Albanian individuals from Kosovo (134), nor with group of 432 Albanian healthy individuals
from Albania (135), except for HLA DRB1*11 allele which was slightly more prevalent in this
study (p=0.042). Both Sulcebes’ studies have the data for HLA-C locus allele frequencies, while
our study has the HLA-DQA1 locus allele frequencies, thus the comparison could not be
performed for these two loci.
The analysis of haplotype frequencies revealed concordant result about HLA-A*02-B*18-
DRB1*11 as the most frequent haplotype in all of these three populations, being the only
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haplotype exceeding the frequency of 5%. The haplotype HLA-A*01-B*08-DRB1*03 was
among first three most common haplotypes in all three populations, present at a frequency of
2-3%. The most striking difference was found for haplotype HLA-A*02-B*51-DRB1*14 which
is the second most common haplotype in our healthy control group with a frequency of 3.6%, but
was not reported as a haplotype exceeding frequency of 1% (0.96%) in both Sulcebes’ studies. In
Allele*Frequencies worldwide populations database (136) this haplotype is furthermore found
with a frequency also lower than 1% in several populations (Macedonia, Italy-Lombardia, Bosnia
and Herzegovina, Croatia, Turkey).
It can be summarized that the HLA allele and haplotype frequencies in healthy control group
used in this study are not significantly different from the allele and haplotype frequencies found
in two other Albanian populations studied so far, although some differences are found which can
be of interest for further population studies of Kosovar Albanian population.
In this study, we provide data, for the first time in Albanian paediatric population, supporting a
strong association between CD and HLA-class II DRB1, DQA1 and DQB1 alleles and
haplotypes, as well as DQ heterodimers. Overall, we found that 95% of children with CD were
DQ2 and/or DQ8 positive, as compared with 40.32% of the healthy individuals. Our results are in
accordance with those reported from the other studies, even though the frequency of HLA-DQ2
and DQ8 heterodimer positivity among patients diagnosed with CD varies among different
populations. This differences in the best way has been described in large HLA-DQ study
conducted in France, Italy, Finland, Norway, and England by Karell et al. They report the range
of HLA DQ heterodimer frequency from the lowest one of 89.4% in Italy to the highest one of
96.7% in England (137). Such heterodimer frequency differences between populations were also
observed in a prospective study in 13 Mediterranean countries (with different percentage of
patients with HLA typing results). As conclusion they report that 77.4% of cases carried the DQ2
heterodimer, 20% the DQ8 heterodimer, whereas 1.9% didn`t carry either of these molecules
(138).
Our results are similar to study performed in a Greek pediatric population, which found out that
95.8% of individuals with CD were DQ2 and/or DQ8 positive, as compared with 32.5% of the
healthy individuals (139). Furthermore, similar results have been reported from some other
European countries (140-144). Anyway, some studies reported even higher heterodimer
frequency in patients. A study from Croatia, reports that 98% of patients with CD were carriers of
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HLA-DQ2 and DQ8 heterodimers (145), while the recent study by Delgado et al. (146) reported
the following incidences: 96.7% of patients were HLA-DQ2 and 4.4% HLA-DQ8 positive,
giving a 100 % HLA-DQ2 and/or HLA-DQ8 positivity in CD patients.
According to Karhus et al. (147) general Danish population has high frequency of either HLA
DQ2 and/or DQ8 allele related (47.7%) and consecutively all individuals with CD were HLA
DQ2 and/or HLA DQ8 positive, with the majority being HLA DQ2.5 positive. The authors are
giving a speculation that the likelihood of DQ2/DQ8 positivity could be attributed to the high
frequency of alleles associated with CD in patients as compared with controls.
On the other hand, the low frequency (76.9%-81.2%) of these alleles in the patients from several
regions of Russia and from Kazakhstan (148-150) can be related also with the other studies
speculations that in general population high frequencies of susceptibility alleles decline from
West to East with low frequencies in populations in Southeast Asia and the virtual absence of
DQ2/DQ8 in Japan.
Low frequency of HLA-DQ2 and/or DQ8 was reported also in two studies performed in CD
patients from Turkey, 76% and 84.7% respectively (151, 152).
In the present study, 18 (30%) patients had two DQ heterodimer copies. HLA epidemiological
studies have shown that HLA-DQ gene dose has a strong quantitative effect on the magnitude of
gluten-specific T cell responses, and these individuals have the highest risk of developing CD
(153). Clerget-Darpoux et al. estimated the risk for developing celiac disease to be 6.8 times
greater for those having a double dose of DQB1*02:01 (154). Vader et al. (155) showed that
HLA-DQ2.5/2.2 heterozygous individuals could express two HLA-DQ2 dimers on antigen-
presenting cells that bind and present all characterized gluten epitopes.
Interesting, the incidence of HLA-DQ8 alone, in double dose or with other heterodimers, in our
CD cases (8.33 %) was slightly lower than in controls (15.3%), with no significant differences,
which is in line with the result reported in literature. According to Murad et al (156) the
frequency of the DQ8 heterodimer (DQB1*03:02 allele) was elevated in patients versus controls,
but uncorrected P value was borderline significant (10.2% vs. 8.6%), while Cabrera et al. (157)
reports slightly higher frequency with no significant differences between patients and control
individuals, 11.22% and 15.31%, respectively. Lower frequency but in line with our results were
Koskinen`s et al. (158) reports of DQ8 frequency of 2.8 %, 6.2% and 6.7% in Hungarian, Finish
and Italian CD patients, respectively.
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In our study, we have found a pronounced increase of the DQA1*02:01, DQA1*05:01,
DQB1*02:01, DQB1*02:02, DRB1*03, and DRB1*07 alleles. These alleles are classically
considered to be associated with CD, as it is shown in other population’s studies as well (159,
160). However, surprisingly, we found no association with DRB1*04 and DQB1*03:02 because,
although 4.16% of the patients carry the DQ8 haplotype, the distribution in the CD population
was lower than in the control group (7.66%). This is an observation that is comparable with
results reported by some other authors (161). The main associated haplotype was DRB1*03–
DQB1*0201–DQA1*0501 (DR3–DQ2) (38.8%), followed by DRB1*07–DQB1*02:02–
DQA1*02:01 (DR7–DQ2) (17.5%) haplotype.
Regarding the three HLA-DQ2 and DQ8 negative patients, two of them carried the haplotype
DRB1*11-DQB1*03:01-DQA1*05:05 (DR5-DQ7), one carrying it in homozygosis. The third
patient, who lacked all HLA-CD susceptibility factors, was a girl with positive serological test
and partial villous atrophy, who responded to a gluten-free diet.
According to the data, originating from different countries the percentage of patients with celiac
disease that are HLA-DQ2 and HLA-DQ8 negative is between 0 and 10%, but there are also
other studies reporting higher percentages (162, 163). In the multicentre study by Karell et al.
(137), out of 6.0% of CD cases lacking the DQ2 or DQ8 heterodimer, 5.6 % of them carried one
half of the DQ2 heterodimer, and 4 (0.4%) were DQ2, DQ8, α5, β2 negative. On the other hand,
Fernández-Bañares et al. (164) showed that 3% of CD patients in Spain might be non-HLA-
DQ2.5/8, half than the frequency observed in the European Genetics Cluster on CD while the
frequency of lacking HLA-DQ8 and the two alleles encoding HLA-DQ2 was 1%. In addition
more recent study performed in Brazilian CD children (165) reports that 3 % of tested patients
were negative for DQ2/DQ8 heterodimer, 2 % showed low risk predisposing alleles and 1%
tested negative for all of predisposing alleles. These results show that the incidence of patients
diagnosed with celiac disease, who are HLA-DQ2, and HLA-DQ8 negative varies among
different populations.
As expected, the most common five-locus haplotype in patients was A*01-B*08-DRB1*03-
DQA1*05:01-DQB1*02:01 with an extremely high frequency (22%). This haplotype is regarded
as a very common in healthy individuals (2.8%), because due to the high polymorphism,
haplotypes in general population are not very often found at a frequencies greater than 5%. This
is an extended, highly conserved haplotype, named AH8.1. It is also a risk factor for several other
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autoimmune diseases (lupus, myasthenia, autoimmune hepatitis, diabetes type 1 etc.) (166), and
in that sense can be regarded as an autoimmune haplotype. As it is a DQ2.5 heterodimer positive
haplotype, it contributes to the most DQ2.5 heterodimer positivity in cis position in patients.
The most frequent haplotype in controls A*02-B*18-DRB1*11 with a frequency of over 6%, was
not found in patients, thus making the calculation of odds ratio not applicable. However, this is a
finding that needs to be clarified by further studies, as this data suggest a protective role for CD
in Kosovar Albanian population. Less pronounced, but similar results are found for haplotype
A*02-B*51-DRB1*14 (4% in controls, 0% in patients). On the other hand, the haplotype A*02-
B*51-DRB1*11 was common in patients as well as in controls, 4.1% (third most common
haplotype) and 2.4% (fourth most common haplotype) respectively.
Interestingly, the incidence of 5-loci extended haplotype A*02-B*50-DRB1*07-DQA1*02:01-
DQB1*02:02 was observed in 4.1 % of our CD cases and in only 0.4% of controls. This
haplotype has been not previously reported as haplotype associated with CD. It is most probable
haplotype of Euro-Asiatic origin, as it is present in Mongolians (HF: 3.2%), in Chaouya
population from Morocco (HF: 2.9%), Manchu (HF: 2.2%), Turks and Kurds (HF: 1.3%),
Spaniards (HF: 1.2%) and Italians (HF: 0.5%) (167-169). Another haplotype that was found in
four patients and not at all found in the control group was A*68-B*44-DRB1*07-DQA1*02:01-
DQB1*02:02.
In Europe, this haplotype has been reported only in populations from Portugal-Azores Island,
Turkey, Italy and Norway-ethnic Norwegians. It clearly shows that this haplotype was migrating
from south to north of Europe or vice-versa. It is interesting to note, that both of these rare
haplotypes, are the ones carrying DQ2.2 heterodimer, which can be of interest for further studies
in CD patients from Kosovo, both paediatric and adult ones.
Our results show that genotype positive for at least one of the CD predisposing heterodimers has
high sensitivity value (95%) in contrast to quite low specificity (40%). On the other hand, high
negative predictive value (96%) was associated with the highest positive predictive value
observed for heterozygous genotype DQ2.5/DQ2.2 of (86%). Our results are in high accordance
with literature results reporting that absence of the corresponding genes virtually excludes a
diagnosis of CD with a very high negative predictive value, while the positive predictive value of
HLA DQ2/DQ8 is however limited as they can be present in approximately 40% of the general
population, most of whom will never develop CD (170).
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Among nine patients clinically suspected (un-confirmed) for CD, all DQ2/DQ8 negative, the
DQA1*05 allele was found in 5 cases, showing the possible association between CD and
DQA1*05 phenotype. There was not found out any correlation according to clinic
symptomatology and HLA heterodimer lacking, but it was shown that 3 out of 4 children
negative for HLA DQ2/DQ8 missed two diagnostic tests (SBB and EMA) while TG2 titres was
less than 10 time of NUL. This may be the explanation of HLA DQ2/DQ8 negativity for these
nine children. To all of them was proposed a gluten challenge with biopsies, because there is
doubt about the initial diagnosis since HLA-DQ2 and HLA-DQ8 were negative and the children
were placed on a GFD without proper testing (32).
We assessed CD-associated HLA-DQ-DR frequencies in Kosovar Albanian patients and controls
to evaluate possible effects of different genetic substrates. Even if many theories and
environmental risk factors are subject to ongoing veriﬁcation - like gluten introduction in
populations, timing of gluten introduction in infants, breastfeeding, composition of microbiota,
metabolic proﬁles, vaccination schedule, infections, use of antibiotics, etc. the high-risk HLA
genotypes at present remain the most important factor affecting CD onset. This study is giving
the evidence to this finding in Kosovar Albanian population, as well.
It must be also stressed that our study had some limitations regarding the sample size; thus,
further studies must be done to overcome these drawbacks, including a broader population, both
in sample size and patients age range.
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7. CONCLUSION
 The diagnosis was primarily suspected on its presentation with classical gastrointestinal
manifestations
 The proportion of cases with diarrhoea 78%, suggest that maybe a sizeable proportion of
cases with atypical presentations are not recognized
 Anorexia and anaemia were the most prevalent extraintestinal manifestation especially in
school children and adolescents
 Girls were almost twice as often affected as boys; gender ratio was 1.9:1
 Quite young age at the time of diagnosis (5.5 years) and the relatively short delay to
diagnosis, appears to be the result of the classic clinical manifestation
 Positive family history for CD was present for 12% of cases, 60% of them siblings, that
shows a significantly increased chance of celiac disease in first and second-degree
relatives
 Anti-tissue transglutaminase 2 (TG2) antibody tests was the most used serological marker
in CD diagnosis
 New 2012`s ESPGHAN criteria was shown to be usefully for CD diagnosis in Kosovo as
in many other resource limited countries due to its cost-effectiveness and the possibility
of reducing the time of diagnosis
 HLA allele and haplotype analysis revealed ancestral HLA-A*01-B*08-DRB1*03-
DQA1*05:01-DQB1*02 as the most frequent haplotype in patients with high statistically
significant increased frequency compared with controls (p<0.0001, OR=10)
 The extended haplotype HLA-A*02-B*50-DRB1*07-DQA1*02:01-DQB1*02:02 is
present in patients with high statistically significant increased frequency compared with
controls (p<0.0001, OR=11) and might be a Kosovar Albanian population specific risk
factor for CD
 The extended haplotype HLA-A*02-B*18-DRB1*11-DQA1*05:05-DQB1*03:01 was the
most frequent haplotype in healthy control group and not at all present in patients, thus
might be a Kosovar Albanian population specific protective factor for CD
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 HLA-DQ heterodimer type analysis revealed DQ2.5 and DQ2.2 heterodimers as two most
frequent heterodimers in patients, representing 58,3% of all heterodimers detected, and
being statistically significantly increased in comparison with controls. Heterodimer
DQ8.3 did not differ in frequency between patients and controls
 The two most frequent heterodimers in controls were DQ5.1 and DQ7.5 representing 52%
of heterodimers detected and both with a statistically significant increased frequency in
comparison with patients
 Heterodimer genotype DQ2.5/X was the most prevalent one (58%), while the second most
frequent genotype was DQ2.5/DQ2.2 (20%), together being present in 78% of patients
and in 17% of controls.
 Genotype positive for DQ2.5 either in a single or double dose was present in 88% of
patients, while genotypes positive for any of two other risk heterodimers were present in
additional 7% of patients. In total, 95.00 % of patients and 40.32% of controls had a
genotype that was positive for at least one of the predisposing DQ heterodimers (HLA-
DQ2.5, DQ8, DQ2.2) (p<0.0001).
 CD was diagnosed in three DQ heterodimer negative patients, two carried DQA1 allele of
DQ2.5 heterodimer (DQA1*05:05) and one was completely negative for any of risk
heterodimer alleles
 Among all detected HLA allele, haplotype and heterodimer polymorphisms as the CD risk
factors, presence of at least one of DQ2.5, DQ8, DQ2.2 heterodimers had the highest
sensitivity (95%) and highest negative predictive value (96%), absence of DQ2.5, DQ8,
DQ2.2 heterodimers in an individual genotype had a highest specificity (60%) and
DQ2.5/DQ2.2 genotype had highest positive predictive value (86%). Haplotype A*02-
B*50-DRB1*07-DQA1*02:01-DQB1*02:02 also had very high positive predictive value
(83%)
 Kosovar Albanian pediatric CD patients present similar distribution of predisposing HLA-
DQ2 and DQ8 heterodimers as in other European and non-European populations but
some HLA genetic factors specific for Kosovar Albanian population have also been
determined
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8. ABSTRACT
Clinical, biochemical and immunogenetical characteristics of celiac disease in Albanian
pediatric patients from Kosovo, Atifete Ramosaj-Morina, 2019
Introduction: Celiac disease is an immune-mediated chronic inflammatory disorder triggered
after gluten ingestion in genetically susceptible individuals. HLA-DQ2 and HLA-DQ8
heterodimers have been recognized as necessary - but not sufficient – genetic factors for the
occurrence of celiac disease.
Aim: To present the clinical and biochemical characteristics in celiac disease Kosovar Albanian
children as well as to analyse HLA class I and class II allele and haplotype polymorphism in
patients and matched controls.
Materials and methods: A total of 72 patients treated for celiac disease from 2005 to 2016 at
Pediatric Clinic, University Clinical Center of Kosovo and 124 age matched, unrelated healthy
children as control group were enrolled in the study. Serum antibody testing and small bowel
biopsies were performed in Kosovo while molecular HLA typing was done in Tissue Typing
Center, UHC Zagreb.
Results: Celiac disease was diagnosed due to classical form of presentation in 78% of patients.
Mean age at the time of diagnosis was 5.5 years, sex distribution showed a female predominance
(1.9:1). Among 60 confirmed celiac disease patients, 95.00 % carried at least one of the risk DQ
heterodimers (HLA-DQ2.5, DQ8, DQ2.2) in comparison with 40.32% of controls (p<0.0001,
OD=28; negative predictive value 96%). None of the nine clinically unconfirmed patients carried
the predisposing DQ heterodimer. The HLA-A*02-B*50-DRB1*07-DQA1*02:01-DQB1*02:02
was found as population specific celiac disease predisposing haplotype with a positive predictive
value of 83%.
Conclusion: Kosovar Albanian pediatric celiac disease patients show the same distribution of
predisposing HLA-DQ2 and DQ8 heterodimers as in other European and non-European
populations but some HLA genetic factors specific for Kosovar Albanian population have also
been determined.
Key words: Celiac disease, HLA, DQ heterodimer, Kosovo Albanian children.
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9. SAŽETAK
Uvod: Celijakija je imunološki posredovana kronična upalna bolest tankog crijeva koja u
genetski predisponiranih osoba, nastaje uslijed prehrane glutenom. Heterodimeri HLA-DQ2 i
HLA-DQ8 su neophodan, ali ne i dostatan, genetički čimbenik za razvoj celijakije.
Cilj: U albanske djece s Kosova s celijakijom prikazati klinička i biokemijska obilježja te
analizirati i usporediti polimorfizam alela i haplotipova HLA razreda I i razreda II u bolesnika i u
zdravoj kontrolnoj skupini.
Materijali i metode: U istraživanje je bilo uključeno 72 djece liječeno s dijagnozom celijakije u
razdoblju od 2005-2016 godine u Klinici za pedijatriju, Sveučilišnog kliničkog centra Kosovo te
124 zdrave, nesrodne djece sukladne dobi, kao kontrolna skupina. Testiranje antitijela te biopsije
sluznice tankog crijeva provedene su na Kosovu, a molekularna tipizacija HLA u Odjelu za
tipizaciju tkiva Kliničkog bolničkog centra Zagreb.
Rezultati: Ukupno je 78% bolesnika dijagnosticirano temeljem očitovanja s klasičnom slikom
bolesti, srednja dob pri postavljanju dijagnoze bila je 5,5 godina, s raspodjelom spolova 1,9:1 u
korist djevojčica. U skupini od 60 bolesnika s klinički potvrđenom dijagnozom, 95% ih je bilo
nositelj barem jednog od rizičnih DQ heterodimera (HLA-DQ2.5, DQ8, DQ2.2), a u kontrolnoj
skupini 40.32% (p<0.0001, OD=28; negativna prediktivna vrijednost 96%). Niti jedan od devet
bolesnika koji su imali klinički nejasnu sliku nije bio nositelj rizičnog heterodimera DQ. HLA-
A*02-B*50-DRB1*07-DQA1*02:01-DQB1*02:02 haplotip je otkriven kao rizični genetski
čimbenik za celijakiju u populaciji Kosova, s pozitivnom prediktivnom vrijednošću 83%.
Zaključak: U albanske djece s Kosova s celijakijom utvrđena je istovjetna učestalost rizičnih
heterodimera HLA-DQ2 i DQ8 kao i u drugim europskim i ne-europskim populacijama, ali uz to
otkriveni su i genetički čimbenici HLA koji su specifični za albansku populaciju s Kosova.
Ključne riječi: celijakija, HLA, DQ heterodimer, albanska djeca s Kosova
81
10. LIST OF REFERENCES
1. Vogten AJ, Peña AS. Coeliac disease: one century after Samuel Gee (1888). Neth J Med.
1987;31(5–6):253-5.
2. Mearin ML. Celiac disease among children and adolescents. Curr Probl Pediatr Adolesc Health
Care. 2007;37(3):86–105.
3. Seah PP, Fry L, Rossiter MA, Hoffbrand AV, Holborow EJ. Anti-reticulin antibodies in
childhood coeliac disease. Lancet Lond Engl. 1971;25;2 (7726):681–2.
4. Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F, Thorsby E. Evidence for a primary
association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med.
1989;169(1):345–50.
5. Palavecino EA, Mota AH, Awad J, Derosa S, Herrera M, Chertkoff L, et al. HLA and celiac
disease in Argentina: involvement of the DQ subregion. Dis Markers. 1990;8(1):5–10.
6. Schuppan D, Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, et al. Identification of the
Autoantigen of Celiac Disease. Ann N Y Acad Sci. 1998;859(1):121–6.
7. Revised criteria for diagnosis of coeliac disease. Report of Working Group of European Society
of Paediatric Gastroenterology and Nutrition. Arch Dis Child. 1990;65(8):909–11.
8. Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S, et al. The prevalence of
celiac disease in Europe: results of a centralized, international mass screening project. Ann Med.
2010;42(8):587–95.
9. Cataldo F, Pitarresi N, Accomando S, Greco L, SIGENP, GLNBI Working Group on Coeliac
Disease. Epidemiological and clinical features in immigrant children with coeliac disease: an
Italian multicentre study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver.
2004;36(11):722–9.
10. Vanciková Z, Chlumecký V, Sokol D, Horáková D, Hamsíková E, Fucíková T, et al. The
serologic screening for celiac disease in the general population (blood donors) and in some high-
risk groups of adults (patients with autoimmune diseases, osteoporosis and infertility) in the
Czech Republic. Folia Microbiol (Praha). 2002;47(6):753–8.
11. Altobelli E, Paduano R, Petrocelli R, Di Orio F. Burden of celiac disease in Europe: a review of
its childhood and adulthood prevalence and incidence as of September 2014. Ann Ig.
2014;26(6):485-98.
82
12. Rostami K, Kerckhaert J, Tiemessen R, von Blomberg BM, Meijer JW, Mulder CJ.
Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease:
disappointing in clinical practice. Am J Gastroenterol. 1999;94(4):888–94.
13. Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, et al. Prevalence
of Celiac disease among children in Finland. N Engl J Med. 2003;348(25):2517–24.
14. Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, et al. Prevalence of celiac
disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch
Intern Med. 2003;163(3):286–92.
15. Cook HB, Burt MJ, Collett JA, Whitehead MR, Frampton CM, Chapman BA. Adult coeliac
disease: prevalence and clinical significance. J Gastroenterol Hepatol. 2000;15(9):1032–6.
16. Comba A, Eren NB, Demir E. Prevalence of celiac disease among school-age children in
Çorum, Turkey. Turk J Gastroenterol. 2018;29(5):595-600.
17. Darada K, Bitar A, Mokadem MA-R, Hashash JG, Green P. Celiac disease in Middle Eastern
and North African countries: a new burden? World J Gastroenterol. 2010;16(12):1449–57.
18. Bai JC, Ciacci C. World Gastroenterology Organisation Global Guidelines: Celiac Disease
February 2017. J Clin Gastroenterol. 2017;51(9):755–68.
19. Lionetti E, Catassi C. New clues in celiac disease epidemiology, pathogenesis, clinical
manifestations, and treatment. Int Rev Immunol. 2011;30(4):219–31.
20. Bodé S, Gudmand-Høyer E. Incidence and prevalence of adult coeliac disease within a
defined geographic area in Denmark. Scand J Gastroenterol. 1996;31(7):694–9.
21. Hawkes ND, Swift GL, Smith PM, Jenkins HR. Incidence and presentation of coeliac disease
in South Glamorgan. Eur J Gastroenterol Hepatol. 2000;12(3):345–9.
22. Collin P, Reunala T, Rasmussen M, Kyrönpalo S, Pehkonen E, Laippala P, et al. High
incidence and prevalence of adult coeliac disease. Augmented diagnostic approach. Scand J
Gastroenterol. 1997;32(11):1129–33.
23. López-Rodríguez MJ, Canal Macías ML, Lavado García JM, Sánchez Belda M, Robledo
Andrés P, Pedrera Zamorano JD. Epidemiological changes in diagnosed coeliac disease in a
population of Spanish children. Acta Paediatr Oslo Nor. 1992. 2003;92(2):165–9.
24. Hoffenberg EJ, MacKenzie T, Barriga KJ, Eisenbarth GS, Bao F, Haas JE, et al. A
prospective study of the incidence of childhood celiac disease. J Pediatr. 2003;143(3):308–14.
83
25. Corrao G, Usai P, Galatola G, Ansaldi N, Meini A, Pelli MA, et al. Estimating the incidence
of coeliac disease with capture-recapture methods within four geographic areas in Italy. J
Epidemiol Community Health. 1996;50(3):299–305.
26. Magazzú G, Bottaro G, Cataldo F, Iacono G, Di Donato F, Patane R, et al. Increasing
incidence of childhood celiac disease in Sicily: results of a multicenter study. Acta Paediatr
Oslo Nor. 1992. 1994;83(10):1065–9.
27. Singh P, Arora S, Singh A, Strand TA, Makharia GK. Prevalence of celiac disease in Asia: A
systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(6):1095–101.
28. Ludvigsson JF, Card TR, Kaukinen K, Bai J, Zingone F, Sanders DS, et al. Screening for
celiac disease in the general population and in high-risk groups. United Eur Gastroenterol J.
2015;3(2):106–20.
29. Dixit R, Lebwohl B, Ludvigsson JF, Lewis SK, Rizkalla-Reilly N, Green PHR. Celiac disease
is diagnosed less frequently in young adult males. Dig Dis Sci. 2014;59(7):1509–12.
30. Rashid M, Cranney A, Zarkadas M, Graham ID, Switzer C, Case S, et al. Celiac disease:
evaluation of the diagnosis and dietary compliance in Canadian children. Pediatrics.
2005;116(6):754-759.
31. Walker MM, Murray JA, Ronkainen J, Aro P, Storskrubb T, D’Amato M, et al. Detection of
celiac disease and lymphocytic enteropathy by parallel serology and histopathology in a
population-based study. Gastroenterology. 2010;139(1):112–9.
32. Husby S, Koletzko S, Korponay-Szabó IR, Mearin ML, Phillips A, Shamir R, et al. European
Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the
diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr. 2012;54(1):136–60.
33. Rostom A, Murray JA, Kagnoff MF. American Gastroenterological Association (AGA)
Institute technical review on the diagnosis and management of celiac disease.
Gastroenterology. 2006;131(6):1981–2002.
34. Molberg O, Mcadam SN, Körner R, Quarsten H, Kristiansen C, Madsen L, et al. Tissue
transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T
cells in celiac disease. Nat Med. 1998;4(6):713–7.
35. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PHR, et al. The Oslo
definitions for coeliac disease and related terms. Gut. 2013;62(1):43–52.
84
36. Fasano A. Clinical presentation of celiac disease in the pediatric population. Gastroenterology.
2005;128(4 Suppl 1): S68-73.
37. Fasano A, Catassi C. Coeliac disease in children. Best Pract Res Clin Gastroenterol.
2005;19(3):467–78.
38. Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest.
2007;117(1):41–9.
39. Megiorni F, Pizzuti A. HLA-DQA1 and HLA-DQB1 in Celiac disease predisposition:
practical implications of the HLA molecular typing. J Biomed Sci. 2012; 19:88.
40. Ontiveros N, Hardy MY, Cabrera-Chavez F. Assessing of Celiac Disease and Nonceliac
Gluten Sensitivity. Gastroenterol Res Pract. 2015; 2015:72395.
41. Louka AS, Sollid LM. HLA in coeliac disease: unravelling the complex genetics of a
complex disorder. Tissue Antigens. 2003;61(2):105–17.
42. Mazzarella G, Maglio M, Paparo F, Nardone G, Stefanile R, Greco L, et al. An
immunodominant DQ8 restricted gliadin peptide activates small intestinal immune response
in in vitro cultured mucosa from HLA-DQ8 positive but not HLA-DQ8 negative coeliac
patients. Gut. 2003;52(1):57–62.
43. Fleckenstein B, Molberg Ø, Qiao S-W, Schmid DG, von der Mülbe F, Elgstøen K, et al.
Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme
specificity and pH influence on the transamidation versus deamidation process. J Biol Chem.
2002;277(37):34109–16.
44. Fleckenstein B, Qiao S-W, Larsen MR, Jung G, Roepstorff P, Sollid LM. Molecular
characterization of covalent complexes between tissue transglutaminase and gliadin peptides.
J Biol Chem. 2004;279(17):17607–16.
45. Hüe S, Mention J-J, Monteiro RC, Zhang S, Cellier C, Schmitz J, et al. A direct ro5le for
NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity.
2004;21(3):367–77.
46. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, et al. Coordinated
induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into
lymphokine-activated killer cells in celiac disease. Immunity. 2004;21(3):357–66.
47. Meresse B, Curran SA, Ciszewski C, Orbelyan G, Setty M, Bhagat G, et al. Reprogramming
of CTLs into natural killer-like cells in celiac disease. J Exp Med. 2006;203(5):1343–55.
85
48. Benelli E, Zin A, Martelossi S. Celiac disease in children. Minerva Pediatr. 2018
49. Green PHR, Krishnareddy S, Lebwohl B. Clinical manifestations of celiac disease. Dig Dis
Basel Switz. 2015;33(2):137–40.
50. Ferrara M, Coppola L, Coppola A, Capozzi L. Iron deficiency in childhood and adolescence:
retrospective review. Hematol Amst Neth. 2006;11(3):183–6.
51. NIH Consensus Development Conference on Celiac Disease. NIH Consens State Sci
Statements. 2004;21(1):1-23.
52. Parzanese I, Qehajaj D, Patrinicola F, Aralica M, Chiriva-Internati M, Stifter S, et al. Celiac
disease: From pathophysiology to treatment. World J Gastrointest Pathophysiol.
2017;8(2):27–38.
53. Rostom A, Dubé C, Cranney A, Saloojee N, Sy R, Garritty C, et al. Celiac disease. Evid Rep
Technol Assess (Summ). 2004;(104):1–6.
54. Bonamico M, Pasquino AM, Mariani P, Danesi HM, Culasso F, Mazzanti L, et al. Prevalence
and clinical picture of celiac disease in Turner syndrome. J Clin Endocrinol Metab.
2002;87(12):5495–8.
55. Korponay-Szabó IR, Dahlbom I, Laurila K, Koskinen S, Woolley N, Partanen J, et al.
Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for coeliac
disease in selective IgA deficiency. Gut. 2003;52(11):1567–71.
56. Ch’ng CL, Jones MK, Kingham JGC. Celiac disease and autoimmune thyroid disease. Clin
Med Res. 2007;5(3):184–92.
57. Gobbi G. Coeliac disease, epilepsy and cerebral calcifications. Brain Dev. 2005;27(3):189–
200.
58. Anania C, De Luca E, De Castro G, Chiesa C, Pacifico L. Liver involvement in pediatric
celiac disease. World J Gastroenterol. 2015 May 21;21(19):5813–22.
59. Eigner W, Bashir K, Primas C, Kazemi-Shirazi L, Wrba F, Trauner M, et al. Dynamics of
occurrence of refractory coeliac disease and associated complications over 25 years. Aliment
Pharmacol Ther. 2017;45(2):364-372.
60. Byström IM, Hollén E, Fälth-Magnusson K, Johansson A. Health-related quality of life in
children and adolescents with celiac disease: from the perspectives of children and parents.
Gastroenterol Res Pract. 2012;2012:986475.
86
61. Durham J, Temples HS. Celiac Disease in the Pediatric Population. J Pediatr Health Care.
2018;32(6):627-631.
62. Wessels MMS, de Rooij N, Roovers L, Verhage J, de Vries W, Mearin ML. Towards an
individual screening strategy for first-degree relatives of celiac patients. Eur J Pediatr.
2018;177(11):1585-1592.
63. Marginean CO, Meliţ LE, Mareş R-C, Mărginean MO, Voidăzan S, Dobreanu M. Clinical
and biological correlations in celiac disease in children: the prospective single experience of a
romanian tertiary center: A case-control study (Strobe-Compliant study). Medicine
(Baltimore). 2017;96(20):6936.
64. 10 Am J Gastroenterol. 2010;105(12):2520–4.
65. Hawamdeh H, Al-Zoubi B, Al Sharqi Y, Qasrawi A, Abdelaziz Y, Barbar M. Association of
Tissue Transglutaminase Antibody Titer with Duodenal Histological Changes in Children
with Celiac Disease. Gastroenterol Res Pract. 2016;2016:6718590.
66. Lewis NR, Scott BB. Systematic review: the use of serology to exclude or diagnose coeliac
disease (a comparison of the endomysial and tissue transglutaminase antibody tests). Aliment
Pharmacol Ther. 2006;24(1):47–54.
67. Lewis NR, Scott BB. Meta-analysis: deamidated gliadin peptide antibody and tissue
transglutaminase antibody compared as screening tests for coeliac disease. Aliment
Pharmacol Ther. 2010;31(1):73–81.
68. Giersiepen K, Lelgemann M, Stuhldreher N, Ronfani L, Husby S, Koletzko S, et al. Accuracy
of diagnostic antibody tests for coeliac disease in children: summary of an evidence report. J
Pediatr Gastroenterol Nutr. 2012;54(2):229–41.
69. Lebwohl B, Rubio-Tapia A, Assiri A, Newland C, Guandalini S. Diagnosis of celiac disease.
Gastrointest Endosc Clin N Am. 2012;22(4):661–77.
70. Rashid M, MacDonald A. Importance of duodenal bulb biopsies in children for diagnosis of
celiac disease in clinical practice. BMC Gastroenterol. 2009; 9:78.
71. Marsh MN. Grains of truth: evolutionary changes in small intestinal mucosa in response to
environmental antigen challenge. Gut. 1990;31(1):111–4.
72. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a
standardized report scheme for pathologists. Eur J Gastroenterol Hepatol. 1999;11(10):1185–
94.
87
73. Dickson BC, Streutker CJ, Chetty R. Coeliac disease: an update for pathologists. J Clin
Pathol. 2006;59(10):1008–16.
74. Plaza-Izurieta L, Fernandez-Jimenez N, Bilbao JR. Genetics of Celiac Disease. HLA and
Non-HLA Genes. In Arranz E, Fernández-Bañares F, Rosell CM, Rodrigo L, Peña AS,
editors. Advances in the Understanding of Gluten Related Pathology and the Evolution of
Gluten-Free Foods. Barcelona, Spain: OmniaScience; 2015. p. 79-104.
75. Murray JA, Moore SB, Van Dyke CT, Lahr BD, Dierkhising RA, Zinsmeister AR, et al. HLA
DQ gene dosage and risk and severity of celiac disease. Clin Gastroenterol Hepatol Off Clin
Pract J Am Gastroenterol Assoc. 2007;5(12):1406–12.
76. Mubarak A, Spierings E, Wolters V, van Hoogstraten I, Kneepkens CM, Houwen R. Human
leukocyte antigen DQ2.2 and celiac disease. J Pediatr Gastroenterol Nutr. 2013;56(4):428-30.
77. Monsuur AJ, de Bakker PIW, Zhernakova A, Pinto D, Verduijn W, Romanos J, et al.
Effective detection of human leukocyte antigen risk alleles in celiac disease using tag single
nucleotide polymorphisms. PloS One. 2008;3(5):2270.
78. Megiorni F, Mora B, Bonamico M, Barbato M, Nenna R, Maiella G, et al. HLA-DQ and risk
gradient for celiac disease. Hum Immunol. 2009;70(1):55-9.
79. Pallav K, Kabbani T, Tariq S, Vanga R, Kelly CP, Leffler DA. Clinical utility of celiac
disease-associated HLA testing. Dig Dis Sci. 2014;59(9):2199–206.
80. Peña-Quintana L, Torres-Galván MJ, Déniz-Naranjo MC, Ortigosa-Castillo L, Ramos-Varela
JC, Calvo-Hernández F, et al. Assessment of the DQ heterodimer test in the diagnosis of
celiac disease in the Canary Islands (Spain). J Pediatr Gastroenterol Nutr. 2003;37(5):604–8.
81. Margaritte-Jeannin P, Babron MC, Bourgey M, Louka AS, Clot F, Percopo S, et al. HLA-DQ
relative risks for coeliac disease in European populations: a study of the European Genetics
Cluster on Coeliac Disease. Tissue Antigens. 2004;63(6):562–7.
82. Piancatelli D, Ben E, Barhdadi I, Oumhani K, Sebastiani P, Colanardi A et al. HLA Typing
and Celiac Disease in Moroccans. Med Sci (Basel). 2017, 6;5(1).
83. Dolinšek J, Micetik-turk D, Urlep-Žužej D, Zagradišnik B, Haimilia K, Holopainen P.
Importance of Celiac Disease Patients Lacking HLA DQ2 or DQ8 Heterodimer in Slovenia.
J Pediatr Gastroenterol Nutr 2006; 42(5): 18-19.
88
84. Smigoc Schweiger D, Mendez A, Kunilo Jamnik S, Bratanic N, Bratina N, Battelino T, et al.
High-risk genotypes HLA-DR3-DQ2/DR3-DQ2 and DR3-DQ2/DR4-DQ8 in co-occurrence
of type 1 diabetes and celiac disease. Autoimmunity. 2016;49(4):240-7.
85. Alarida K, Harown J, Di Pierro MR, Drago S, Catassi C. HLA-DQ2 and -DQ8 genotypes in
celiac and healthy Libyan children. Dig Liver Dis. 2010; 42:425-7.
86. Stanković B, Radlović N, Leković Z, Ristić D, Radlović V, Nikčević G, et al. HLA
genotyping in pediatric celiac disease patients. Bosn J Basic Med Sci. 2014 Aug
16;14(3):171-6.
87. Rostami-Nejad M, Romanos J, Rostami K, et al. Allele and haplotype frequencies for HLA-
DQ in Iranian celiac disease patients. World J Gastroenterol 2014; 20: 6302-8.
88. Sumník Z, Kolousková S, Cinek O, et al. HLA-DQA1*05DQB1*0201 positivity predisposes
to celiac disease in Czech diabetic children. Acta Paediatr 2000; 89: 1426-30.
89. Neuhausen SL, Weizman Z, Camp NJ, et al. HLA DQA1-DQB1 genotypes in Bedouin
families with celiac disease. Hum Immunol 2002; 63: 502-7.
90. Selleski N, Almeida LM, Almeida FC, Pratesi CB, Nóbrega YKM, Gandolfi L. Prevalence of
celiac disease predisposing genotypes, including HLA-DQ2.2 variant, in Brazilian children.
Arq Gastroenterol. 2018 Jan-Mar;55(1):82-85.
91. Karell K, Louka AS, Moodie SJ, Ascher H, Clot F, Greco L, et al. HLA types in celiac
disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: Results from the
European Genetics Cluster on Celiac Disease. Hum Immunol. 2003;64(4):469–77.
92. Bascuñán KA, Vespa MC, Araya M. Celiac disease: understanding the gluten-free diet. Eur J
Nutr. 2017;56(2):449–59.
93. Kurppa K, Collin P, Mäki M, Kaukinen K. Celiac disease and health-related quality of life.
Expert Rev Gastroenterol Hepatol. 2011;5(1):83–90.
94. Sugai E, Nachman F, Váquez H, González A, Andrenacci P, Czech A, et al. Dynamics of
celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment
of compliance with treatment. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study
Liver. 2010;42(5):352–8.
89
95. Nachman F, del Campo MP, González A, Corzo L, Vázquez H, Sfoggia C, et al. Long-term
deterioration of quality of life in adult patients with celiac disease is associated with treatment
noncompliance. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver.
2010;42(10):685–91.
96. Raehsler SL, Choung RS, Marietta EV, Murray JA. Accumulation of Heavy Metals in
People on a Gluten-Free Diet. Clin Gastroenterol Hepatol. 2018;16(2):244-251.
97. Elli L, Rossi V, Conte D, Ronchi A, Tomba C, Passoni M, et al. Increased mercury levels in
patients with celiac disease following a gluten-free regimen. Gastroenterol Res Pract. 2015;
2015: 953042
98. Rajpoot P, Sharma A, Harikrishnan S, et al. Adherence to gluten-free diet and barriers to
adherence in patients with celiac disease. Indian J Gastroenterol. 2015; 34:380–386.
99. Glissen Brown JR1, Singh P. Coeliac disease. Paediatr Int Child Health. 2018; 13:1-9
100. Stein J, Schuppan D. Coeliac Disease - New Pathophysiological Findings and Their
Implications for Therapy. Viszeralmedizin. 2014;30(3):156–65.
101.Leffler DA, Kelly CP, Abdallah HZ, Colatrella AM, Harris LA, Leon F, et al. A randomized,
double-blind study of larazotide acetate to prevent the activation of celiac disease during
gluten challenge. Am J Gastroenterol. 2012;107(10):1554–62.
102.Ciacci C, Maiuri L, Russo I, Tortora R, Bucci C, Cappello C, et al. Efficacy of budesonide
therapy in the early phase of treatment of adult coeliac disease patients with malabsorption:
an in vivo/in vitro pilot study. Clin Exp Pharmacol Physiol. 2009;36(12):1170–6.
103.Lobatón T, Vermeire S, Van Assche G, Rutgeerts P. Review article: anti-adhesion therapies
for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(6):579–94.
104. Jüse U, Arntzen M, Højrup P, Fleckenstein B, Sollid LM. Assessing high affinity binding to
HLA-DQ2.5 by a novel peptide library based approach. Bioorg Med Chem.
2011;19(7):2470–7.
105.Alex Lancaster, Richard M Single, Owen D Solberg, Mark P Nelson, and Glenys Thomson.
2007b. “PyPop update - a software pipeline for large-scale multilocus population genomics”.
Tissue Antigens. 69 Suppl 1. 192-197.
106. Steens RFR, Csizmadia CGDS, George EK, Ninaber MK, Hira Sing RA, Mearin ML. A
national prospective study on childhood celiac disease in the Netherlands 1993-2000: an
increasing recognition and a changing clinical picture. J Pediatr. 2005;147(2):239–43.
90
107.Ress K, Luts K, Rägo T, Pisarev H, Uibo O. Nationwide study of childhood celiac disease
incidence over a 35-year period in Estonia. Eur J Pediatr. 2012;171(12):1823–8.
108.Tucci F, Astarita L, Abkari A, Abu-Zekry M, Attard T, Ben Hariz M, et al. Celiac disease in
the Mediterranean area. BMC Gastroenterol. 2014;14:24.
109. Fortunato F, Martinelli D, Cozza V, Ciavarella P, Valente A, Cazzato T, et al. Italian family
paediatricians’ approach and management of celiac disease: a cross-sectional study in Puglia
Region, 2012. BMC Gastroenterol. 2014;14:38.
110.Tanpowpong P, Broder-Fingert S, Katz AJ, Camargo CA. Age-related patterns in clinical
presentations and gluten-related issues among children and adolescents with celiac disease.
Clin Transl Gastroenterol. 2012;3:e9.
111.McGowan KE, Castiglione DA, Butzner JD. The changing face of childhood celiac disease
in north america: impact of serological testing. Pediatrics. 2009;124(6):1572–8.
112. Savilahti E, Kolho K-L, Westerholm-Ormio M, Verkasalo M. Clinics of coeliac disease in
children in the 2000s. Acta Paediatr Oslo Nor 1992. 2010;99(7):1026–30.
113.Namatovu F, Sandström O, Olsson C, Lindkvist M, Ivarsson A. Celiac disease risk varies
between birth cohorts, generating hypotheses about causality: evidence from 36 years of
population-based follow-up. BMC Gastroenterol. 2014;14:59.
114.Cilleruelo ML, Roman-Riechmann E, Sanchez-Valverde F, Donat E, Manuel-Ramos J,
Martín-Orte E, et al. Spanish national registry of celiac disease: incidence and clinical
presentation. J Pediatr Gastroenterol Nutr. 2014;59(4):522–6.
115.Garampazzi A, Rapa A, Mura S, Capelli A, Valori A, Boldorini R, et al. Clinical pattern of
celiac disease is still changing. J Pediatr Gastroenterol Nutr. 2007;45(5):611–4.
116.Roma E, Panayiotou J, Karantana H, Constantinidou C, Siakavellas SI, Krini M, et al.
Changing pattern in the clinical presentation of pediatric celiac disease: a 30-year study.
Digestion. 2009;80(3):185–91.
117.Radlovic NP, Mladenovic MM, Lekovic ZM, Stojsic ZM, Radlovic VN. Influence of early
feeding practices on celiac disease in infants. Croat Med J. 2010;51(5):417–22.
118.Vajpayee S, Sharma SD, Gupta R, Goyal A, Sharma A. Early Infant Feeding Practices May
Influence the Onset of Symptomatic Celiac Disease. Pediatr Gastroenterol Hepatol Nutr.
2016;19(4):229–35.
91
119.Akobeng AK, Ramanan AV, Buchan I, Heller RF. Effect of breast feeding on risk of coeliac
disease: a systematic review and meta‐analysis of observational studies. Arch Dis Child.
2006;91(1):39–43.
120.Lurz E, Scheidegger U, Spalinger J, Schöni M, Schibli S. Clinical presentation of celiac
disease and the diagnostic accuracy of serologic markers in children. Eur J Pediatr.
2009;168(7):839–45.
121.Demir H, Yüce A, Koçak N, Ozen H, Gürakan F. Celiac disease in Turkish children:
presentation of 104 cases. Pediatr Int Off J Jpn Pediatr Soc. 2000;42 (5):483–7.
122.Dinler G, Atalay E, Kalayci AG. Celiac disease in 87 children with typical and atypical
symptoms in Black Sea region of Turkey. World J Pediatr WJP. 2009;5 (4):282–6.
123.Nurminen S, Kivelä L, Huhtala H, Kaukinen K, Kurppa K. Extraintestinal manifestations
were common in children with coeliac disease and were more prevalent in patients with more
severe clinical and histological presentation. Acta Paediatr. 2018.
124. Ivarsson A, Persson LA, Nyström L, Ascher H, Cavell B, Danielsson L, et al. Epidemic of
coeliac disease in Swedish children. Acta Paediatr Oslo Nor 1992. 2000;89(2):165–71.
125.Çekın AH, Çekın Y, Sezer C. Celiac disease prevalence in patients with iron deficiency
anemia. Turk J Gastroenterol Off J Turk Soc Gastroenterol. 2012;23(5):490–5.
126.Uçardağ D, Güliter S, Ceneli O, Yakaryilmaz F, Atasoy P, Cağlayan O. Celiac disease
prevalence in patients with iron deficiency anemia of obscure origin. Turk J Gastroenterol Off
J Turk Soc Gastroenterol. 2009;20(4):266–70.
127.Baudon J-J, Johanet C, Absalon YB, Morgant G, Cabrol S, Mougenot J-F. Diagnosing celiac
disease: a comparison of human tissue transglutaminase antibodies with antigliadin and
antiendomysium antibodies. Arch Pediatr Adolesc Med. 2004;158(6):584–8.
128. Singh P, Arora S, Lal S, Strand TA, Makharia GK. Risk of Celiac Disease in the First- and
Second-Degree Relatives of Patients with Celiac Disease: A Systematic Review and Meta-
Analysis. Am J Gastroenterol. 2015;110(11):1539-48.
129.Altamimi E. Celiac Disease in South Jordan. Pediatr Gastroenterol Hepatol Nutr. 2017;
20(4):222-226.
130.Rubio-Tapia A, Van Dyke CT, Lahr BD, Zinsmeister AR, El-Youssef M, Moore SB et
al. Predictors of family risk for celiac disease: a population-based study. Clin Gastroenterol
Hepatol 2008;6: 983–987.
92
131.Bonamico M, Ferri M, Mariani P, Nenna R, Thanasi E, Luparia RP, et al. Serologic and
genetic markers of celiac disease: a sequential study in the screening of first degree
relatives. J Pediatr Gastroenterol Nutr 2006;42:150–154.
132.Castro-Antunes MM, Magalhães R, Nobre JMM Duarte BP, Silva GA. et al. Celiac disease
in first-degree relatives of patients. J Pediatr (Rio J) 2010;86:331–336.
133.Oliveira GN, Mohan R, Fagbemi A. Review of celiac disease presentation in a pediatric
tertiary centre. Arq Gastroenterol. 2018;55(1):86-93.
134. Sulcebe G, Cuenod M, Sanchez-Mazas A, Tiercy JM, Zhubi B, Shyti E, et al. Human
leukocyte antigen-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in an
Albanian population from Kosovo. Int J Immunogenet. 2013;40(2):104-7.
135. Sulcebe G, Shyti E. HLA-A, -B, -C, -DRB1 and -DQB1 allele and haplotype frequencies in
a population of 432 healthy unrelated individuals from Albania. Hum Immunol.
2016;77(8):620-621.
136.Gonzalez-Galarza FF, Takeshita LY, Santos EJ, Kempson F, Maia MH, Silva AL, Silva AL,
Ghattaoraya GS, Alfirevic A, Jones AR and Middleton D Allele frequency net 2015 update:
new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations
Nucleic Acid Research 2015 28: D784-8.
137.Karell K, Louka AS, Moodie SJ, Ascher H, Clot F, Greco L, et al. HLA types in celiac
disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the
European Genetics Cluster on Celiac Disease. Hum Immunol. 2003;64(4):469–77.
138.Tucci F, Astarita L, Abkari A, Abu-Zekry M, Attard T, Ben Hariz. Celiac disease in the
Mediterranean area. BMC Gastroenterol. 2014;11;14:24
139.Krini M, Chouliaras G, Kanariou M, Varela I, Spanou K, Panayiotou J et al. HLA class II
high-resolution genotyping in Greek children with celiac disease and impact on disease
susceptibility. Pediatr Res. 2012; 72(6):625-30.
140.Hernández-Charro B, Donat E, Miner I, Aranburu E, Sánchez-Valverde F, Ramos-Arroyo
MA. Modifying effect of HLA haplotypes located trans to DQB1*02-DRB1*03 in celiac
patients of Southern Europe. Tissue Antigens 2008;71:213–8.
141.Margaritte-Jeannin P, Babron MC, Bourgey M, Louka AS, Clot F, Percopo S, et al. HLA-
DQ relative risks for coeliac disease in European populations: a study of the European
Genetics Cluster on Coeliac Disease. Tissue Antigens. 2004;63(6):562–7.
93
142. Piccini B, Vascotto M, Serracca L, Luddi A, Margollicci MA, Balestri P, et al. HLA-DQ
typing in the diagnostic algorithm of celiac disease. Rev Esp Enferm Dig. 2012;104(5):248-
54.
143.Wroblova K, Kolorz M, Pav I, Horakova Z, Filipova P, Bartos M, et al. Frequencies of
HLA-DQ2 and HLA-DQ8 haplotypes in Czech and Slovak coeliac patients and the healthy
population. Acta Biochim Pol. 2014;61(1):191-3.
144.Donat E, Planelles D, Capilla-Villanueva A, Montoro JA, Palau F, Ribes Koninckx C.
Allelic distribution and the effect of haplotype combination for HLA type II loci in the celiac
disease population of the Valencian community (Spain). Tissue Antigens 2009;73:255–61
145.Žunec R, Grubić Z, Jurčić Z, Peršić M, Kaštelan A, Kerhin-Brkljačić V. HLA-DQ2
heterodimer in the diagnosis of celiac disease. Biochemia medica. 2004; 14:119-124.
146.Delgado JF, Amengual MJ, Veraguas A, Rodríguez E, de Los Santos MM, Guallarte MP.
Paediatric celiac patients carrying the HLA-DR7-DQ2 and HLA-DR3-DQ2 haplotypes
display small clinical differences. Acta Paediatr 2014;103: 238-42.
147. Kårhus LL, Thuesen BH, Skaaby T, Rumessen JJ, Linneberg A. The distribution of HLA
DQ2 and DQ8 haplotypes and their association with health indicators in a general Danish
population. United European Gastroenterol J. 2018;6(6):866-878.
148. Savvateeva LV, Erdes SI, Antishin AS, Zamyatnin AA Jr. Overview of Celiac Disease in
Russia: Regional Data and Estimated Prevalence. J Immunol Res.2017:2314813.
149.Kondratyeva E. I., Yankina G. N. Incidence of polymorphic variants of HLA DQA1 and
DQB1 genes in patients with celiac disease in Tomsk and Krasnodar. Pediatric
Nutrition. 2012;10:11–14.
150.Kurtanov H. A., Danilova A. L., Yakovleva A. E., Savvina A. D., Maximova H. P. Genetic
research of HLA genes I and II class—DRB1, DQA1, DQB1 in patients with celiac
disease. The Bulletin of Hematology. 2015;11:44–47
151.Basturk A, Artan R, Yilmaz A. The incidence of HLA-DQ2/DQ8 in Turkish children with
celiac disease and a comparison of the geographical distribution of HLA-DQ. Przeglad
Gastroenterol. 2017;12(4):256–61.
152.Kuloğlu Z, Doğanci T, Kansu A, Demirçeken F, Duman M, Tutkak H, et al. HLA types in
Turkish children with celiac disease. Turk J Pediatr 2008;50: 515-20
94
153.Louka AS, Nilsson S, Olsson M, Talseth B, Lie BA, Ek J, et al. HLA in coeliac disease
families: a novel test of risk modification by the 'other' haplotype when at least one
DQA1*05-DQB1*02 haplotype is carried. Tissue Antigens.vol. 2002; 60:147-54.
154.Clerget-Darpoux F, Bouguerra F, Kastally R, Semana G, Babron MC, Debbabi A, et al.
High risk genotypes for celiac disease. C R Acad Sci III 1994;317:931–936
155.Vader W, Stepniak D, Kooy Y, et al. The HLA-DQ2 gene dose effect in celiac disease is
directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl
Acad Sci USA. 2003;100:12390-5.
156.Murad H, Jazairi B, Khansaa I, Olabi D, Khouri L. HLA-DQ2 and -DQ8 genotype
frequency in Syrian celiac disease children: HLA-DQ relative risks evaluation. MC
Gastroenterol. 2018;18(1):70.
157.Cabrera CM, Méndez-López IM, Caballero A. Risk variation in celiac disease in a
population from Southern Spain: evaluating the influence of the DQB1*02:02 allele
frequency. Scand J Gastroenterol. 2018;53(3):266-272.
158.Koskinen L, Romanos J, Kaukinen K, Mustalahti K, Korponay-Szabo I, Barisani D, et al.
Cost-effective HLA typing with tagging SNPs predicts celiac disease risk haplotypes in the
Finnish, Hungarian, and Italian populations. Immunogenetics. 2009;61(4):247-56
159.Michalski JP, McCombs CC, Arai T, Elston RC, Cao T, McCarthy CF, et al. HLA-DR, DQ
genotypes of celiac disease patients and healthy subjects from the West of Ireland. Tissue
Antigens 1996;47:127–33.
160.Tighe MR, Hall MA, Ashkenazi A, Siegler E, Lanchbury JS, Ciclitira PJ. Celiac disease
among Ashkenazi Jews from Israel. A study of the HLA class II alleles and their associations
with disease susceptibility. Hum Immunol 1993;38:270–6.
161. Johnson TC, Diamond B, Memeo L, Negulescu H, Hovhanissyan Z, Verkarre V, et al.
Relationship of HLA-DQ8 and severity of celiac disease: comparison of New York and
Parisian cohorts. Clin Gastroenterol Hepatol 2004:2:888–94.
162.Vidales MC, Zubillaga P, Zubillaga I, Alfonso-Sánchez MA. Allele and haplotype
frequencies for HLA class II (DQA1 and DQB1) loci in patients with celiac disease from
Spain. Hum Immunol. 2004;65(4):352-8.
163. Pallav K, Kabbani T, Tariq S, Vanga R, Kelly CP, Leffler DA. Clinical utility of celiac
disease-associated HLA testing. Dig Dis Sci 2014; 59: 2199-206
95
164. Fernández-Bañares F, Arau B, Dieli-Crimi R, Rosinach M, Nuñez C, Esteve M. Systematic
Review and Meta-analysis Show 3% of Patients With Celiac Disease in Spain to be Negative
for HLA-DQ2.5 and HLA-DQ8. Clin Gastroenterol Hepatol. 2017;15(4):594-596.
165. Selleski N, Almeida LM, Almeida FC, Pratesi CB, Nóbrega YKM, Gandolfi L. Prevalence
of celiac disease predisposing genotypes, including HLA-DQ2.2 variant, in Brazilian children.
Arq Gastroenterol. 2018;55(1):82-85.
166.Candore G, Lio D, Colonna Romano G, Caruso C. Pathogenesis of autoimmune
diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions.
Autoimmun Rev. 2002;1(1-2):29-35.
167. Imanishi T, Akaza T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies
for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T,
eds.HLA 1991.Vol I. Oxford: Oxford University Press, 1992:1065–1220.
168.Arnaiz-Villena A, Karin M, Bendikuze N, Gomez-Casado E, Moscoso J, Silvera C et al.
HLA alleles and haplotypes in the Turkish population: relatedness to Kurds, Armenians and
other Mediterraneans. Tissue Antigens. 2001;57(4):308-17.
169.Canossi A, Piancatelli D, Aureli A, Oumhani K, Ozzella G, Del Beato T. Correlation
between genetic HLA class I and II polymorphisms and anthropological aspects in the
Chaouya population from Morocco (Arabic speaking). Tissue Antigens. 2010;76(3):177-93.
170.Tye-Din JA., Cameron DJ, Daveson AJ, Day AS, Dellsperger P, Hogan C, et al. Appropriate
clinical use of human leukocyte antigen typing for coeliac disease: an Australasian
perspective. Internal medicine journal, 45(4), 441-50.
96
11. CURRICULUM VITAE
Atifete Ramosaj-Morina was born on October 25, 1980, in Decan, Kosovo, where she completed
primary school and gymnasium.
She has graduated in Faculty of Medicine, University of Prishtina, Kosovo in 2005.
In 2014 she has finished successfully the specialization in field of Pediatric, at Pediatric Clinic,
University Clinical Center of Kosova, were she has started working as Pediatrician.
Starting from 2007 she works as teaching assistant in Department of Anatomy, Faculty of
Medicine, University of Prishtina.
In the academic year 2011/2012, she enrolled in the PhD Program on “Biomedicine and Health
Sciences” at the University of Zagreb, in Croatia.
She is author of several scientific papers published in peer reviewed journals as well as presented
in international and national conferences.
She has attended many professional training and seminars.
She is married mother of two children.
